image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
afc67efd98d1174a57c6e260361ddc98aa16385e39ac19c064b4c35d1cf562db.png | simple | <table><tr><td> </td><td>2011 total<sup>a</sup></td><td>2011 indoor tanned</td><td>2013 total<sup>a</sup></td><td>2013 indoor tanned</td><td>Chi-square</td><td><i>P</i> value</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>8,316</td><td>1420 (17.6%)</td>... | <table><tr><td></td></tr><tr><td>Sex</td></tr><tr><td>Female</td></tr><tr><td>Male</td></tr><tr><td>Combined</td></tr><tr><td>Grade Level</td></tr><tr><td>8th grade</td></tr><tr><td>10th grade</td></tr><tr><td>12th grade</td></tr><tr><td>Race/ethnicity</td></tr><tr><td>American Indian</td></tr><tr><td>Asian</td></tr><t... | <table><tr><td>2011 totala</td><td>2011 indoor tanned</td><td>2013 totala</td><td>2013 indoor tanned</td><td>Chi-square</td><td>P value</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>8,316</td><td>1420 (17.6%)</td><td>8004</td><td>882 (11.7%)</td><td>10.2</td><td>0.002</td></tr><tr><td>... |
23ecea3e008801c32203cb4a212688fd06dc12e309aa762282644d4903f6035d.png | complex | <table><tr><td rowspan="2">Variable</td><td>GPCP<sup>a</sup></td><td>EPG<sup>b</sup></td><td>MD<sup>c</sup></td></tr><tr><td><i>n</i> = 35</td><td><i>n</i> = 21</td><td><i>n</i> = 20</td></tr><tr><td></td><td>Median; mean (SD)</td><td>Median; mean (SD)</td><td>Median; mean (SD))</td></tr><tr><td>Age in years</td><td>86... | <table><tr><td rowspan="2">Variable</td><td>GPCPa</td><td>EPGb</td><td>MDc</td></tr><tr><td>n = 35</td><td>n = 21</td><td>n = 20</td></tr><tr><td></td><td>Median; mean (SD)</td><td>Median; mean (SD)</td><td>Median; mean (SD))</td></tr><tr><td>Age in years</td><td>86.0; 85.0 (7.5)</td><td>87.0; 84.8 (7.2)</td><td>87.5; ... | <table><tr><td>ne functional status (Barthel Index)</td><td> 55.5 (23.3)</td><td>.8 (19.2)</td><td>58.4 (20.9)</td></tr><tr><td>Baseline cognitive function (SMMSEe score)*</td><td>25.0; 23.3 (5.7)</td><td>19.5; 19.2 (5.8)</td><td>23.5; 23.4 (4.3)</td></tr><tr><td>Baseline depressive symptoms (GDS-15f score)</td><td>6.0... |
c660b5c144eb34136587bf8a5ee04ebde4cc6711f467f80fc10ab5a459c16a06.png | simple | <table><tr><td></td><td>SiteLight</td><td>FINDMAP</td><td>3DEX</td><td>MIMOP</td><td>Mapitope</td><td>MIMOX</td></tr><tr><td>Coded in</td><td>C++</td><td>C++</td><td>VB</td><td>PHP</td><td>C++</td><td>Perl</td></tr><tr><td>Operating System</td><td>Linux</td><td>Not stated</td><td>Windows</td><td>Platform independent</t... | <table><tr><td></td><td>SiteLight</td><td>FINDMAP</td><td>3DEX</td><td>MIMOP</td><td>Mapitope</td><td>MIMOX</td></tr><tr><td>Coded in</td><td>C++</td><td>C++</td><td>VB</td><td>PHP</td><td>C++</td><td>Perl</td></tr><tr><td>Operating System</td><td>Linux</td><td>Not stated</td><td>Windows</td><td>Platform independent</t... | <table><tr><td>Structure Dependent</td><td>yes</td><td>no</td><td>yes</td><td>yes/no</td><td>yes</td><td>yes</td></tr></table> |
031229b26a41842f5b03065a03b3e8550b8dd36b2bdb9d4c340443550b48023e.png | simple | <table><tr><td>Rank</td><td>Suggestions for solutions to delayed diagnosis in primary care</td><td>Total priority score</td><td>Type of interventions to decrease delayed diagnosis</td><td>Breakdown points in the diagnostic process</td></tr><tr><td>1</td><td>To have more rigorous systems in place for communicating abnor... | <table><tr><td>Rank</td><td>Suggestions for solutions to delayed diagnosis in primary care</td><td>Total priority score</td><td>Type of interventions to decrease delayed diagnosis</td><td>Breakdown points in the diagnostic process</td></tr><tr><td>1</td><td>To have more rigorous systems in place for communicating abnor... | <table><tr><td>10</td><td>Have easier access to secondary care for the patients that GPs are worried about</td><td>83.9</td><td>Structured-process change</td><td>Referral & consultation</td></tr></table> |
3f085eb205c6094e98d377924c28f501d53e50367596f75308c96eee316e3a18.png | complex | <table><tr><td colspan="6">Neural-specific measurements: low-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td><i>P</i>value</td><td>FDR</td><td>Count</td><td>Fold enrichment</td></tr><tr><td>0006351</td><td>Transcription</td><td>4 × 10<sup>−10</sup></td><td>2 × 10<sup>−7</sup></... | <table><tr><td colspan="6">Neural-specific measurements: low-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td>Pvalue</td><td>FDR</td><td>Count</td><td>Fold enrichment</td></tr><tr><td>0006351</td><td>Transcription</td><td>4 × 10−10</td><td>2 × 10−7</td><td>58</td><td>2.5</td></tr><tr><td></td><td>svp... | <table><tr><td colspan="6">Neural-specific measurements: low-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td>Pvalue</td><td>FDR</td><td>Count</td><td>Fold enrichment</td></tr><tr><td colspan="6">Neural-specific measurements: high-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td>Pv... |
da3b87fb1760925bc17f113b1222f74bacc4c0ab6dd88de9ef90bc02ae76f58e.png | complex | <table><tr><td> </td><td> </td><td colspan="3">Treatment</td></tr><tr><td>Variety</td><td>Tissue</td><td>Control</td><td>Mild stress</td><td>Severe stress</td></tr><tr><td>Costal</td><td>Needles</td><td>DCNC</td><td>DCNM</td><td>DCNS</td></tr><tr><td> </td><td>Wood</td><td>DCWC</td><td>DCWM</td><td>DCWS</td></tr><tr><t... | <table><tr><td></td><td></td><td colspan="3">Treatment</td></tr><tr><td>Variety</td><td>Tissue</td><td>Control</td><td>Mild stress</td><td>Severe stress</td></tr></table> | <table><tr><td></td><td></td><td colspan="3">Treatment</td></tr><tr><td>Costal</td><td>Needles</td><td>DCNC</td><td>DCNM</td><td>DCNS</td></tr><tr><td></td><td>Wood</td><td>DCWC</td><td>DCWM</td><td>DCWS</td></tr><tr><td>Interior</td><td>Needles</td><td>DINC</td><td>DINM</td><td>DINS</td></tr><tr><td></td><td>Wood</td>... |
cce5b40676d07c42182dc5814a7e9b03d24b48bf04868b97f57dfa3b326c9708.png | simple | <table><tr><td>Type of Insurance</td><td>Estimated cases in 2005 (a)</td><td>Estimated cases in 2005 (b)</td><td>Incremental financial burden of moving from OC to LC by government (c)</td><td>Household's off-set cost from moving from OC to LC (d)</td><td>Net financial burden to society (e)</td></tr><tr><td>UC</td><td>8... | <table><tr><td>Type of Insurance</td><td>Estimated cases in 2005 (a)</td><td>Estimated cases in 2005 (b)</td><td>Incremental financial burden of moving from OC to LC by government (c)</td><td>Household's off-set cost from moving from OC to LC (d)</td><td>Net financial burden to society (e)</td></tr><tr><td>UC</td><td>8... | <table><tr><td>CSMBS</td><td>2,000</td><td>1,600</td><td>19,200,000</td><td>8,000,000</td><td>11,200,000</td></tr><tr><td>Total</td><td>10,000</td><td>8,000</td><td>96,000,000</td><td>40,000,000</td><td>56,000,000</td></tr></table> |
8a9389e6930d25f4408a161348bdaca8fcc5e1e9f3550f5fc4e6e69b187f50c0.png | complex | <table><tr><td>Theme</td><td colspan="3">Balancing between ideality and reality</td></tr><tr><td>Categories</td><td>Limitation</td><td>Self-regulation</td><td>Companionship</td></tr><tr><td>Subcategories</td><td>Insufficiency</td><td>Guilt</td><td>Belonging</td></tr><tr><td></td><td>Adaptation</td><td>Motivation</td><t... | <table><tr><td>Theme</td><td colspan="3">Balancing between ideality and reality</td></tr><tr><td>Categories</td><td>Limitation</td><td>Self-regulation</td><td>Companionship</td></tr></table> | <table><tr><td>Theme</td><td colspan="3">Balancing between ideality and reality</td></tr><tr><td>Subcategories</td><td>Insufficiency</td><td>Guilt</td><td>Belonging</td></tr><tr><td></td><td>Adaptation</td><td>Motivation</td><td>Pleasure</td></tr></table> |
65770b220f4d15cb9e0025f0711edeeb46cec34e8801f9b36eb722f4892a2f1f.png | simple | <table><tr><td></td><td>A (<i>n</i>= 1930)</td><td>B (<i>n</i>= 1938)</td><td>C (<i>n</i>= 1969)</td><td>Total (<i>N</i>= 5837)</td></tr><tr><td>What would you say was the design of the study?</td><td></td><td></td><td></td><td></td></tr><tr><td>Two separate surveys of student drinking</td><td>323 (17%)</td><td>322 (17... | <table><tr><td></td><td>A (n= 1930)</td><td>B (n= 1938)</td><td>C (n= 1969)</td><td>Total (N= 5837)</td></tr><tr><td>What would you say was the design of the study?</td><td></td><td></td><td></td><td></td></tr><tr><td>Two separate surveys of student drinking</td><td>323 (17%)</td><td>322 (17%)</td><td>290 (15%)</td><td... | <table><tr><td>No</td><td>276 (77%)</td><td>251 (79%)</td><td>288 (79%)</td><td>815 (79%)</td></tr><tr><td>Yes</td><td>82 (23%)</td><td>66 (21%)</td><td>75 (21%)</td><td>223 (21%)</td></tr></table> |
2503a1c4249b56ea3aa7ce3d8ee58e5bc9dc1f49b9893312346a98f6aa405aa8.png | complex | <table><tr><td></td><td>Incidental PTMCs</td><td>Non-incidental PTMCs</td><td><i>P</i> value</td></tr><tr><td>Number of patients</td><td>274</td><td>61</td><td></td></tr><tr><td>Age at diagnosis</td><td>49.1 ± 12.5 (range 16 – 76) years</td><td>47.9 ± 13.1 (range 18–81) years</td><td>0.485</td></t... | <table><tr><td></td><td>Incidental PTMCs</td><td>Non-incidental PTMCs</td></tr><tr><td>Number of patients</td><td>274</td><td>61</td></tr><tr><td>Age at diagnosis</td><td>49.1 ± 12.5 (range 16 – 76) years</td><td>47.9 ± 13.1 (range 18–81) years</td></tr><tr><td rowspan="2">Gender</td><td>226F (82.5 %)</td><td>38F (62.3... | <table><tr><td>P value</td></tr><tr><td></td></tr><tr><td>0.485</td></tr><tr><td rowspan="2"><0.001</td></tr><tr></tr><tr><td><0.001</td></tr><tr><td>–</td></tr><tr><td>0.147</td></tr><tr><td>0.917</td></tr><tr><td rowspan="2">0.047</td></tr><tr></tr><tr><td rowspan="2">0.352</td></tr><tr></tr><tr><td rowspan="2">0.055... |
9948409aa706d9975d32aac37aa5df4fc96e924b83b31ea897540fabbad71550.png | simple | <table><tr><td>Hausa IPAQ-SF</td><td>Total (N = 102)</td><td>Women (n = 46)</td><td>Men (n = 56)</td></tr><tr><td></td><td>ICC (95% CI)</td><td>ICC (95% CI)</td><td>ICC (95%CI)</td></tr><tr><td>Vigorous PA (Min week<sup>-1</sup>)</td><td>0.73 (0.55-0.84)</td><td>0.44 (-0.19-0.81)</td><td>0.82 (0.67-0.91)</td></tr><tr><... | <table><tr><td>Hausa IPAQ-SF</td><td>Total (N = 102)</td><td>Women (n = 46)</td><td>Men (n = 56)</td></tr><tr><td></td><td>ICC (95% CI)</td><td>ICC (95% CI)</td><td>ICC (95%CI)</td></tr></table> | <table><tr><td>Vigorous PA (Min week-1)</td><td>0.73 (0.55-0.84)</td><td>0.44 (-0.19-0.81)</td><td>0.82 (0.67-0.91)</td></tr><tr><td>Moderate PA (Min week-1)</td><td>0.33 (0.12-0.51)</td><td>0.35 (0.05-0.59)</td><td>0.31 (0.01-0.56)</td></tr><tr><td>Walking (Min week-1)</td><td>0.56 (0.39-0.69)</td><td>0.43 (0.10-0.67)... |
4434270d84725907dcbed5df4a82d0aeeb91dbfe79eed346b971d78ad52ca041.png | complex | <table><tr><td>Item</td><td>Total case number (436)</td><td>Normal renal function group (176)</td><td>Slight decrease group (141)</td><td>Moderate and severe decrease group (119)</td></tr><tr><td>Gender (male/female) (case)</td><td>322/114</td><td>118/58</td><td>100/41</td><td>104/15</td></tr><tr><td>Age (year)</td><td... | <table><tr><td>Item</td></tr><tr><td>Gender (male/female) (case)</td></tr><tr><td>Age (year)</td></tr><tr><td>Cardiac function classification (grade)</td></tr><tr><td>II</td></tr><tr><td>III</td></tr><tr><td>IV</td></tr></table> | <table><tr><td>Total case number (436)</td><td>Normal renal function group (176)</td><td>Slight decrease group (141)</td><td>Moderate and severe decrease group (119)</td></tr><tr><td>322/114</td><td>118/58</td><td>100/41</td><td>104/15</td></tr><tr><td>79 (60, 98)</td><td>67 (63, 85)</td><td>78 (65, 89)a</td><td>81 (71... |
c598a15054c5dce006815c7889303e34e352ae79a5f89006fcf1138d58592f2c.png | simple | <table><tr><td>Factors</td><td>P</td><td>Odds</td><td>95 % CI</td></tr><tr><td>Age</td><td>0.0875</td><td>1.27742</td><td>0.96462–1.69165</td></tr><tr><td>DD</td><td>0.3805</td><td>0.9947</td><td>0.98294–1.00659</td></tr><tr><td>DAS28</td><td>0.0401</td><td>0.00284</td><td>0.00001–0.76627</td></tr><tr... | <table><tr><td>Factors</td><td>P</td></tr><tr><td>Age</td><td>0.0875</td></tr><tr><td>DD</td><td>0.3805</td></tr><tr><td>DAS28</td><td>0.0401</td></tr><tr><td>PSL</td><td>0.3289</td></tr><tr><td>MTX</td><td>0.9742</td></tr><tr><td>Stage</td><td>0.8398</td></tr><tr><td>Class</td><td>0.9247</td></tr></table> | <table><tr><td>Odds</td><td>95 % CI</td></tr><tr><td>1.27742</td><td>0.96462–1.69165</td></tr><tr><td>0.9947</td><td>0.98294–1.00659</td></tr><tr><td>0.00284</td><td>0.00001–0.76627</td></tr><tr><td>1.53217</td><td>0.65064–3.60805</td></tr><tr><td>0.98265</td><td>0.34078–2.83353</td></tr><tr><td>0.64611</td><td>0.00936... |
69b50d17fbcb89bf8ff0df1b34e78d5346c2637bce7b7729a7d1b67abd3ad5ee.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="2">NTU<sup><i>a</i></sup></td><td colspan="2">TS<sup><i>b</i></sup></td></tr><tr><td><i>n</i><sup><i>c</i></sup></td><td>Percent (SE)</td><td><i>n</i><sup><i>c</i></sup></td><td>Percent (SE)</td></tr><tr><td>Age (years)</td></tr><tr><td>12–19</td><td>752</td><t... | <table><tr><td rowspan="2">Variable</td><td colspan="2">NTUa</td><td colspan="2">TSb</td></tr><tr><td>nc</td><td>Percent (SE)</td><td>nc</td><td>Percent (SE)</td></tr><tr><td>Age (years)</td><td colspan="4"></td></tr></table> | <table><tr><td>12–19</td><td>752</td><td>14.9 (0.91)</td><td>104</td><td>7.16 (0.93)</td></tr><tr><td>20–39</td><td>563</td><td>28.9 (1.52)</td><td>205</td><td>44.4 (3.48)</td></tr><tr><td>40–59</td><td>459</td><td>33.9 (1.56)</td><td>172</td><td>36.5 (3.32)</td></tr><tr><td>≥ 60</td><td>522</td><td>22.2 (2.22)</td><td... |
ca5c610c88e2e35de1ff2f7db2f9d4b25e873edafaa8a4a7481eb00aa383b353.png | simple | <table><tr><td></td><td><i>n</i></td><td>%</td><td>Days</td><td>IQR</td></tr><tr><td>Six-month mortality</td><td>165</td><td>35.6%</td><td></td><td></td></tr><tr><td>ICU mortality</td><td>84</td><td>17.1%</td><td></td><td></td></tr><tr><td>Hospital mortality</td><td>132</td><td>26.9%</td><td></td><td></td></tr><tr><td>... | <table><tr><td></td><td>n</td><td>%</td><td>Days</td><td>IQR</td></tr></table> | <table><tr><td>Six-month mortality</td><td>165</td><td>35.6%</td><td></td><td></td></tr><tr><td>ICU mortality</td><td>84</td><td>17.1%</td><td></td><td></td></tr><tr><td>Hospital mortality</td><td>132</td><td>26.9%</td><td></td><td></td></tr><tr><td>Length of ventilation</td><td></td><td></td><td>11</td><td>6–20</td></... |
863ad493e6a40f6cbe1604be1128256f45cac71ddeeb302cfd188b31602b483c.png | complex | <table><tr><td>Characteristics</td><td>SLLP1-positive</td><td>SLLP1-negative</td><td>Sig.</td></tr><tr><td>Total (N = 394)</td><td>99 (25.1)</td><td>296 (74.9)</td><td></td></tr><tr><td colspan="4">Age at time of sample collection (years)</td></tr><tr><td> ≤60</td><td>64 (21.1)</td><td>240 (78.9)</td><td><i>0.001... | <table><tr><td>Characteristics</td><td>SLLP1-positive</td><td>SLLP1-negative</td><td>Sig.</td></tr><tr><td>Total (N = 394)</td><td>99 (25.1)</td><td>296 (74.9)</td><td></td></tr><tr><td colspan="4">Age at time of sample collection (years)</td></tr><tr><td>≤60</td><td>64 (21.1)</td><td>240 (78.9)</td><td>0.001</td></tr>... | <table><tr><td>Characteristics</td><td>SLLP1-positive</td><td>SLLP1-negative</td><td>Sig.</td></tr><tr><td><8.5</td><td>55 (22.4)</td><td>190 (77.6)</td><td></td></tr><tr><td colspan="4">Serum calcium (mmol/L)</td></tr><tr><td>≤2.6</td><td>79 (22.8)</td><td>267 (77.2)</td><td>0.015</td></tr><tr><td>>2.6</td><td>9 (47.4... |
a50bb65317dcd7c9c1d8bac7cdf7d6d53e65a46cfb21cf6b819d298066bbf376.png | complex | <table><tr><td colspan="5">(a) Results from sham and temporal lobe epilepsy rats after 6 weeks of treatment with NLRP1 siRNA or control siRNA</td></tr><tr><td rowspan="2"></td><td colspan="2">Within 24 h post-stimulation</td><td colspan="2">On the 6th week post-treatment</td></tr><tr><td>Number</td><td>Rate (%)</td><td... | <table><tr><td colspan="5">(a) Results from sham and temporal lobe epilepsy rats after 6 weeks of treatment with NLRP1 siRNA or control siRNA</td></tr><tr><td rowspan="2"></td><td colspan="2">Within 24 h post-stimulation</td><td colspan="2">On the 6th week post-treatment</td></tr><tr><td>Number</td><td>Rate (%)</td><td... | <table><tr><td>TLE + Control siRNA</td><td>18/18</td><td>100</td><td>14/18</td><td>77.8</td></tr><tr><td>TLE + NLRP1 siRNA</td><td>18/18</td><td>100</td><td>8/18</td><td>44.4a</td></tr><tr><td colspan="5">(b) Results from sham and TLE rats after 6 weeks of treatment with Caspase-1 siRNA or control siRNA</td></tr><tr><t... |
7c1a28432b40914902803dd0bbbf2d486520185e884f3e61e12364fb4fcc9b30.png | complex | <table><tr><td></td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>TUG</td><td>N (#dead)</td><td>Seconds, mean (SD)</td><td>N (#dead)</td><td>Seconds, mean (SD)</td></tr><tr><td>1 (quickest)</td><td>128 (58)</td><td>8.2 (1.0)</td><td>125 (46)</td><td>8.4 (1.2)</td></tr><tr><td>2</td><td>80 (52)</td><td>... | <table><tr><td></td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>TUG</td><td>N (#dead)</td><td>Seconds, mean (SD)</td><td>N (#dead)</td><td>Seconds, mean (SD)</td></tr><tr><td>1 (quickest)</td><td>128 (58)</td><td>8.2 (1.0)</td><td>125 (46)</td><td>8.4 (1.2)</td></tr><tr><td>2</td><td>80 (52)</td><td>... | <table><tr><td></td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>TUG</td><td>N (#dead)</td><td>Seconds, mean (SD)</td><td>N (#dead)</td><td>Seconds, mean (SD)</td></tr><tr><td>5 (slowest)</td><td>72 (53)</td><td>19.1 (10.3)</td><td>94 (51)</td><td>23.2 (12.4)</td></tr><tr><td>Total</td><td>438 (261)</... |
b9d13ff8b08fe7eff15ad33821f5f5864e6120fe6be5763a6ddea498063f096a.png | complex | <table><tr><td rowspan="2">Sensor Locations</td><td colspan="7">Year 2012</td><td colspan="2">Year 2013</td></tr><tr><td>March 19</td><td>April 23</td><td>May 30</td><td>July 26</td><td>September 7</td><td>October 19</td><td>December 19</td><td>January 23</td><td>March 10</td></tr><tr><td>1-1-1</td><td>42.4</td><td>42<... | <table><tr><td rowspan="2">Sensor Locations</td><td colspan="7">Year 2012</td><td>Year 2013</td></tr><tr><td>March 19</td><td>April 23</td><td>May 30</td><td>July 26</td><td>September 7</td><td>October 19</td><td>December 19</td><td>January 23</td></tr><tr><td>1-1-1</td><td>42.4</td><td>42</td><td>40.5</td><td>39</td><... | <table><tr><td>Year 2013</td></tr><tr><td>March 10</td></tr><tr><td>35.2</td></tr><tr><td>−35</td></tr><tr><td>−37.9</td></tr><tr><td>41.6</td></tr><tr><td>−66.6</td></tr><tr><td>−38.4</td></tr><tr><td>−20.1</td></tr><tr><td>−48</td></tr><tr><td>−22.2</td></tr><tr><td>11.5</td></tr><tr><td>−82.5</td></tr><tr><td>−63.2<... |
84610d8a1f5f6dc8199a8abc17e5c702b34791e5090c618925c7548d70e03942.png | simple | <table><tr><td>Concentration mIU/ml</td><td>Vaccination protection</td><td>Vaccination recommendation</td><td>Before vaccination</td><td>After vaccination</td></tr><tr><td><= 30</td><td>No</td><td>Basic immunization</td><td>0</td><td>0</td></tr><tr><td>]30 – 100]</td><td>Not surely guaranteed</td><td>Booster v... | <table><tr><td>Concentration mIU/ml</td><td>Vaccination protection</td><td>Vaccination recommendation</td><td>Before vaccination</td><td>After vaccination</td></tr><tr><td><= 30</td><td>No</td><td>Basic immunization</td><td>0</td><td>0</td></tr><tr><td>]30 – 100]</td><td>Not surely guaranteed</td><td>Booster vaccinatio... | <table><tr><td>]1000 – 5000]</td><td>Long term</td><td>Control in 5–10 years</td><td>41</td><td>6</td></tr><tr><td>> 5000</td><td>Extremely high</td><td>Control in 10 years</td><td>9</td><td>79</td></tr></table> |
db86d1d7645cbf0a1b7607e0d2a0babca8bdd6f5e0c09f6f46b3bd8016984e4a.png | simple | <table><tr><td></td><td><i>Oocyte</i></td><td><i>1-cell</i></td><td><i>2-cell</i></td><td><i>4-cell</i></td><td><i>8-cell</i></td><td><i>Morula</i></td><td><i>ICM</i></td><td><i>TE</i></td></tr><tr><td>Mouse embryos*</td><td>14 h</td><td>24–26 h</td><td>36 h</td><td>48 h</td><td>60 h</td><td>72 h</td><td>96 h</td... | <table><tr><td></td><td>Oocyte</td><td>1-cell</td><td>2-cell</td><td>4-cell</td><td>8-cell</td><td>Morula</td><td>ICM</td><td>TE</td></tr><tr><td>Mouse embryos*</td><td>14 h</td><td>24–26 h</td><td>36 h</td><td>48 h</td><td>60 h</td><td>72 h</td><td>96 h</td><td>96 h</td></tr><tr><td>Pig in viv</td><td></td><td>24</td>... | <table><tr><td></td><td>Oocyte</td><td>1-cell</td><td>2-cell</td><td>4-cell</td><td>8-cell</td><td>Morula</td><td>ICM</td><td>TE</td></tr><tr><td>o embryos**</td><td>24 h after estrus</td><td> h</td><td>5 h</td><td>72 h</td><td></td><td>8–115 h</td><td>h</td><td>160 h</td></tr><tr><td>Pig SCNT embryos***</td><td>In vit... |
f6b3e8c30ee694665e4f0d2576f21e233e9fde0d1951757301f97287f6d8b079.png | complex | <table><tr><td rowspan="2">Condition</td><td colspan="2">Experiment 1</td><td colspan="2">Experiment 2</td></tr><tr><td>93 Hz</td><td>109 Hz</td><td>217 Hz</td><td>233 Hz</td></tr><tr><td>Attend-Low</td><td>4.7 ± 1.6</td><td>4.8 ± 1.8</td><td>6.2 ± 1.8</td><td>6.4 ± 2.1</td></tr><tr><td>Attend-High<... | <table><tr><td rowspan="2">Condition</td><td colspan="2">Experiment 1</td><td colspan="2">Experiment 2</td></tr><tr><td>93 Hz</td><td>109 Hz</td><td>217 Hz</td><td>233 Hz</td></tr><tr><td>Attend-Low</td><td>4.7 ± 1.6</td><td>4.8 ± 1.8</td><td>6.2 ± 1.8</td><td>6.4 ± 2.1</td></tr><tr><td>Attend-High</td><td>4.4 ± 2.2</t... | <table><tr><td>Attend-Visual (high stream first)</td><td>5.5 ± 3.1</td><td>4.9 ± 1.8</td><td>5.7 ± 3.3</td><td>7.1 ± 3.2</td></tr></table> |
7f207ac9526744b1581faa7d46556edb7f889b653da44d3e97ec2f2f7585d174.png | complex | <table><tr><td>Mod.</td><td>Mol. exp.</td><td>wt (<i>CEN</i> vec)</td><td><i>trm82∆</i> (<i>CEN TRM82</i>)</td><td><i>trm82∆</i> (<i>CEN</i> vec)</td><td><i>trm82∆</i> (<i>CEN trm82-K223L</i>)</td><td><i>trm82∆</i> (<i>CEN trm82-K223R</i>)</td></tr><tr><td colspan="7">30 °C</td></tr><tr><td... | <table><tr><td>Mod.</td><td>Mol. exp.</td><td>wt (CEN vec)</td><td>trm82∆ (CEN TRM82)</td><td>trm82∆ (CEN vec)</td><td>trm82∆ (CEN trm82-K223L)</td><td>trm82∆ (CEN trm82-K223R)</td></tr><tr><td colspan="7">30 °C</td></tr><tr><td>m7G</td><td>1</td><td>0.41 ± 0.04</td><td>0.34 ± 0.03</td><td><0.03</td><td>0.21 ± 0.01</td... | <table><tr><td>Mod.</td><td>Mol. exp.</td><td>wt (CEN vec)</td><td>trm82∆ (CEN TRM82)</td><td>trm82∆ (CEN vec)</td><td>trm82∆ (CEN trm82-K223L)</td><td>trm82∆ (CEN trm82-K223R)</td></tr><tr><td>Cm</td><td>1</td><td>0.98 ± 0.08</td><td>1.00 ± 0.14</td><td>0.91 ± 0.02</td><td>0.93 ± 0.05</td><td>0.90 ± 0.04</td></tr><tr>... |
07b63e186416917487c8bcdc874b4119cb0d87effa65c4f83d3f3b6a796d9ac5.png | simple | <table><tr><td>Period</td><td>Total biopsies (n)</td><td>Adequate biopsies (n,%)</td><td>Suboptimal biopsies (n,%)</td><td>Inadequate biopsies (n,%)</td><td>Difference in adequacy (%)*</td><td>p value</td></tr><tr><td>1</td><td>127</td><td>40 (31%)</td><td>43 (34%)</td><td>44 (35%)</td><td>NA</td><td>NA</td></tr><tr><t... | <table><tr><td>Period</td><td>Total biopsies (n)</td><td>Adequate biopsies (n,%)</td><td>Suboptimal biopsies (n,%)</td><td>Inadequate biopsies (n,%)</td><td>Difference in adequacy (%)*</td><td>p value</td></tr></table> | <table><tr><td>1</td><td>127</td><td>40 (31%)</td><td>43 (34%)</td><td>44 (35%)</td><td>NA</td><td>NA</td></tr><tr><td>2</td><td>432</td><td>311 (72%)</td><td>54 (13%)</td><td>67 (16%)</td><td>+40% (31, 50)</td><td>< 0.0001</td></tr><tr><td>3</td><td>104</td><td>94 (90%)</td><td>2 (2%)</td><td>8 (8%)</td><td>+18% (8, 2... |
7cb9a56563c21910dde4f194dd923b8c12b28b384f6ef0791fdf90a9186949b8.png | complex | <table><tr><td rowspan="3">Input layer</td><td colspan="5">Hidden layer</td></tr><tr><td>Neuron 1</td><td>Neuron 2</td><td>Neuron 3</td><td>Neuron 4</td><td>Neuron 5</td></tr><tr><td>Bias</td><td>−0.756</td><td>−0.715</td><td>−0.521</td><td>1.154</td><td>−1.304</td></tr><tr><td>Awareness</td><td... | <table><tr><td rowspan="3">Input layer</td><td colspan="5">Hidden layer</td></tr><tr><td>Neuron 1</td><td>Neuron 2</td><td>Neuron 3</td><td>Neuron 4</td><td>Neuron 5</td></tr><tr><td colspan="5"></td></tr><tr><td>Bias</td><td>−0.756</td><td>−0.715</td><td>−0.521</td><td>1.154</td><td>−1.304</td></tr><tr><td>Awareness</... | <table><tr><td>kill</td><td>4</td><td>0.090</td><td>20</td><td>.561</td><td>0.332</td></tr><tr><td>Attitude</td><td>−0.554</td><td>0.374</td><td>0.312</td><td>−0.060</td><td>0.151</td></tr><tr><td>Social capital</td><td>0.017</td><td>0.801</td><td>0.392</td><td>−0.718</td><td>0.558</td></tr><tr><td>Damage severity</td>... |
e3b0c4ee37631994979a8bc60abc4605e22619caa957bfc8d17016586b6d2bdc.png | complex | <table><tr><td>Lakes</td><td>Metals</td><td>Pb</td><td>Cd</td><td>Cu</td><td>Fe</td><td>Mn</td></tr><tr><td rowspan="2">Futala</td><td>BII</td><td>0.14 ± 0.24</td><td>0.09 ± 0.33</td><td>0.08 ± 0.83</td><td>49.0 ± 0.33</td><td>1.23 ± 0.49</td></tr><tr><td>AII</td><td>0.32 ± 0.89</td><td>0.... | <table><tr><td>Lakes</td><td>Metals</td></tr><tr><td rowspan="2">Futala</td><td>BII</td></tr><tr><td>AII</td></tr><tr><td rowspan="2">Gandhi Sagar</td><td>BII</td></tr><tr><td>AII</td></tr><tr><td rowspan="2">Ambazari</td><td>BII</td></tr><tr><td>AII</td></tr><tr><td>PL**</td><td>-</td></tr></table> | <table><tr><td>Pb</td><td>Cd</td><td>Cu</td><td>Fe</td><td>Mn</td></tr><tr><td>0.14 ± 0.24</td><td>0.09 ± 0.33</td><td>0.08 ± 0.83</td><td>49.0 ± 0.33</td><td>1.23 ± 0.49</td></tr><tr><td>0.32 ± 0.89</td><td>0.33 ± 0.58</td><td>4.40 ± 0.72</td><td>169.1 ± 0.82</td><td>2.60 ± 0.67</td></tr><tr><td>0.19 ± 0.29</td><td>0.... |
788d4d3d3a45c2bbea1b28286fdddc2fe8b81cc69ae16b0f8420b76d0ebd8a43.png | complex | <table><tr><td>Variables</td><td colspan="2">Recurrence free survival</td><td><i>P</i></td></tr><tr><td> </td><td>RR</td><td>95% CI</td><td> </td></tr><tr><td>Ulinastatin administration</td><td>0.149</td><td>0.063-0.351</td><td><0.05</td></tr><tr><td>TNM</td><td>1.812</td><td>0.652-5.038</td><td>0.254</td></tr><tr><... | <table><tr><td>Variables</td><td colspan="2">Recurrence free survival</td><td>P</td></tr><tr><td></td><td>RR</td><td>95% CI</td><td></td></tr><tr><td>Ulinastatin administration</td><td>0.149</td><td>0.063-0.351</td><td><0.05</td></tr><tr><td>TNM</td><td>1.812</td><td>0.652-5.038</td><td>0.254</td></tr></table> | <table><tr><td>Variables</td><td colspan="2">Recurrence free survival</td><td>P</td></tr><tr><td>Alcohol consumption</td><td>2.066</td><td>0.909-4.344</td><td>0.757</td></tr><tr><td>Smoking</td><td>1.088</td><td>0.534-2.217</td><td>0.817</td></tr><tr><td>Gender</td><td>0.916</td><td>0.425-1.973</td><td>0.822</td></tr><... |
467f1a58ec41d1bc85789a0bea66abfd5b535ce2e2a8bdb1f5d328a7b91f1463.png | complex | <table><tr><td></td><td colspan="7">Urine iodine levels <i>n</i> (%)</td></tr><tr><td><i>Age group (yrs)</i></td><td><i><20</i></td><td><i>20–49</i></td><td><i>50–149</i></td><td><i>150–249</i></td><td><i>250–499</i></td><td><i>500</i></td><td><i>Total</i></td></tr><tr><td> <20</td><td>2 (... | <table><tr><td></td><td colspan="7">Urine iodine levels n (%)</td></tr><tr><td>Age group (yrs)</td><td><20</td><td>20–49</td><td>50–149</td><td>150–249</td><td>250–499</td><td>500</td><td>Total</td></tr><tr><td><20</td><td>2 (16.67)</td><td>2 (16.67)</td><td>3 (25.00)</td><td>1 (8.33)</td><td>2 (16.67)</td><td>2 (16.67... | <table><tr><td>25–29</td><td>2 (5.71)</td><td>2 (5.71)</td><td>8 (22.86)</td><td>2 (5.71)</td><td>7 (20.00)</td><td>14 (40.00)</td><td>35</td></tr><tr><td>30–34</td><td>3 (12.50)</td><td>3 (12.50)</td><td>7 (29.17)</td><td>6 (25.00)</td><td>1 (4.17)</td><td>4 (16.67)</td><td>24</td></tr><tr><td>35–39</td><td>2 (11.76)<... |
bdc572304c483ed3fb0d41ec66e22346addb23d985d257207b62f9edb59a8aa5.png | simple | <table><tr><td>Calculation (cm<sup>−1</sup>)</td><td>Solid (cm<sup>−1</sup>)</td><td>SERS-Ag (cm<sup>−1</sup>)</td><td>SERS-Au (cm<sup>−1</sup>)</td><td>Assignments</td></tr><tr><td>606 (w)</td><td>615 (w)</td><td>626 (w)</td><td>626 (w)</td><td>δ(C–C–C)ip δ(S–C–... | <table><tr><td>Calculation (cm−1)</td><td>Solid (cm−1)</td><td>SERS-Ag (cm−1)</td><td>SERS-Au (cm−1)</td><td>Assignments</td></tr><tr><td>606 (w)</td><td>615 (w)</td><td>626 (w)</td><td>626 (w)</td><td>δ(C–C–C)ip δ(S–C–N)ip</td></tr><tr><td>748 (m)</td><td>778 (m)</td><td>782 (vs)</td><td>783 (m)</td><td>δ(C–H)oop</td>... | <table><tr><td>1139 (w)</td><td>1118 (w)</td><td>1116 (w)</td><td>1116 (w)</td><td>δ(C–H)ip</td></tr><tr><td>1158 (m)</td><td>1154 (w)</td><td>1147 (m)</td><td>1147 (w)</td><td>δ(C–H)ip</td></tr><tr><td>1215 (w)</td><td>1255 (m)</td><td>1239 (w)</td><td>-</td><td>υ ring</td></tr><tr><td>1270 (s)</td><td>1277 (s)</td><t... |
3b7108eb382d654d38b913f92d8229fa4a77ce15844f9bb589411334949375ae.png | simple | <table><tr><td>Genotype</td><td>GeneID</td><td>log2 ratio</td><td>P-value</td><td>q-value</td><td>Gene description</td></tr><tr><td>R2</td><td>Comp133037_c0</td><td>7.0454</td><td>1.82E-08</td><td>4.59E-07</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV ... | <table><tr><td>Genotype</td><td>GeneID</td><td>log2 ratio</td><td>P-value</td><td>q-value</td><td>Gene description</td></tr><tr><td>R2</td><td>Comp133037_c0</td><td>7.0454</td><td>1.82E-08</td><td>4.59E-07</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV ... | <table><tr><td>Genotype</td><td>GeneID</td><td>log2 ratio</td><td>P-value</td><td>q-value</td><td>Gene description</td></tr><tr><td></td><td>Comp143318_c0</td><td>5.5908</td><td>4.28E-14</td><td>2.24E-12</td><td>Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = ... |
61e797e1e02333b5ba41902c3e5bc355f2e3a69c0f3cd45b846b526d5d4c5fbd.png | complex | <table><tr><td colspan="2"></td><td colspan="2">Complete data<i>N</i> = 11,920</td><td colspan="2">Missing data<i>N</i> = 879</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>Mean (SE)</td><td>27.8</td><td>(0.10)</td><td>28.4</td><td>(0.28)</td></tr><tr><td>Age (y)</td><td>Mean (SE)</td><td>46.2</td><td>(0.28)</td><td>4... | <table><tr><td colspan="2"></td><td colspan="2">Complete dataN = 11,920</td><td colspan="2">Missing dataN = 879</td></tr><tr><td>BMI (kg/m2)</td><td>Mean (SE)</td><td>27.8</td><td>(0.10)</td><td>28.4</td><td>(0.28)</td></tr><tr><td>Age (y)</td><td>Mean (SE)</td><td>46.2</td><td>(0.28)</td><td>47.8</td><td>(1.2)</td></t... | <table><tr><td colspan="2"></td><td>Complete dataN = 11,920</td><td>Missing dataN = 879</td></tr><tr><td rowspan="6">Poverty index</td><td>(%)</td><td></td><td></td></tr><tr><td>Poor</td><td>15.4%</td><td>15.2%</td></tr><tr><td>Near poor</td><td>5.6%</td><td>9.1%</td></tr><tr><td>Low income</td><td>14.8%</td><td>17.5%<... |
6969343b70575c1ff221b1b1fee3fb85d74fdf4cdf659ef24ff7a57bcef6450d.png | simple | <table><tr><td>Analysis*</td><td>Left ventricular mass (SD) in grams while on CHD</td><td>Left ventricular mass (SD) in grams after conversion to INHD</td><td>Change in LVM (SD) in grams</td><td>p-value</td></tr><tr><td>Primary (n = 37)</td><td>219 ± 66</td><td>186 ± 69</td><td>-32 ± 58</td><td>0.002</td... | <table><tr><td>Analysis*</td><td>Left ventricular mass (SD) in grams while on CHD</td><td>Left ventricular mass (SD) in grams after conversion to INHD</td><td>Change in LVM (SD) in grams</td><td>p-value</td></tr><tr><td>Primary (n = 37)</td><td>219 ± 66</td><td>186 ± 69</td><td>-32 ± 58</td><td>0.002</td></tr></table> | <table><tr><td>Analysis*</td><td>Left ventricular mass (SD) in grams while on CHD</td><td>Left ventricular mass (SD) in grams after conversion to INHD</td><td>Change in LVM (SD) in grams</td><td>p-value</td></tr><tr><td>Secondary (n = 31)</td><td>215 ± 71</td><td>174 ± 62</td><td>-40 ± 56</td><td>0.0004</td></tr></tabl... |
1c64ae5e1a40d8e9cbbdbf29ae8113ff45828dedf1cb655b477218b99ab4e2ae.png | complex | <table><tr><td>Participants’ Smoking and Vaping Use at Time of Interview</td><td>Daily</td><td>Weekly</td><td>Monthly</td><td>Total No. of Participants</td></tr><tr><td>Dual users</td><td></td><td></td><td></td><td></td></tr><tr><td>Smoking status</td><td>5</td><td>4</td><td>0</td><td rowspan="2">9</td></tr><tr><... | <table><tr><td>Participants’ Smoking and Vaping Use at Time of Interview</td><td>Daily</td><td>Weekly</td><td>Monthly</td><td>Total No. of Participants</td></tr><tr><td>Dual users</td><td></td><td></td><td></td><td></td></tr><tr><td>Smoking status</td><td>5</td><td>4</td><td>0</td><td rowspan="2">9</td></tr><tr><td>Vap... | <table><tr><td>Participants’ Smoking and Vaping Use at Time of Interview</td><td>Daily</td><td>Weekly</td><td>Monthly</td><td>Total No. of Participants</td></tr><tr><td>Vapers</td><td></td><td></td><td></td><td></td></tr><tr><td>Vaping status</td><td>6</td><td>1</td><td>0</td><td>7</td></tr></table> |
f38b39411a81344573d005a0009b581270477fe4cb7ae6e6f3999e31968004f0.png | complex | <table><tr><td></td><td>No treatment intensification</td><td>Treatment intensification</td></tr><tr><td>Age, years, mean (SD)</td><td>52.6 (12.6)</td><td>51.0 (12.4)</td></tr><tr><td>Sex, <i>n</i> (% female)</td><td>46 (78.9)</td><td>39 (68.4)</td></tr><tr><td colspan="3">Treatment arm</td></tr><tr><td> Early remission... | <table><tr><td></td><td>No treatment intensification</td></tr><tr><td>Age, years, mean (SD)</td><td>52.6 (12.6)</td></tr><tr><td>Sex, n (% female)</td><td>46 (78.9)</td></tr><tr><td colspan="2">Treatment arm</td></tr><tr><td>Early remission</td><td>46.2</td></tr><tr><td>MTX + SSZ + HCQ + prednisone</td><td>20.9</td></t... | <table><tr><td>Treatment intensification</td></tr><tr><td>51.0 (12.4)</td></tr><tr><td>39 (68.4)</td></tr><tr><td>Treatment arm</td></tr><tr><td>57.2</td></tr><tr><td>19.9</td></tr><tr><td>16.0</td></tr><tr><td>6.7</td></tr><tr><td>19 (9–32)</td></tr><tr><td>47 (84.5)</td></tr><tr><td>35 (61.9)</td></tr><tr><td>34 (63.... |
1a20120cb8c17190e7e24c191b7e87d3d915ec96579d8c86d06bcf6d3528e329.png | simple | <table><tr><td>Zn</td><td>Supplemented</td><td>Analyzed Zn</td></tr><tr><td>source</td><td>Zn (mg/kg)</td><td>content (mg/kg)<sup>a</sup></td></tr><tr><td>Basal diet</td><td>0</td><td>25.00</td></tr><tr><td>ZnO</td><td>8</td><td>39.18</td></tr><tr><td>Bioplex Zn</td><td>8</td><td>32.64</td></tr><tr><td>ZnO</td><td>40</... | <table><tr><td>Zn</td><td>Supplemented</td><td>Analyzed Zn</td></tr><tr><td>source</td><td>Zn (mg/kg)</td><td>content (mg/kg)a</td></tr></table> | <table><tr><td>Basal diet</td><td>0</td><td>25.00</td></tr><tr><td>ZnO</td><td>8</td><td>39.18</td></tr><tr><td>Bioplex Zn</td><td>8</td><td>32.64</td></tr><tr><td>ZnO</td><td>40</td><td>68.46</td></tr><tr><td>Bioplex Zn</td><td>40</td><td>70.29</td></tr></table> |
262721d03e0847c12b8ee8581601aeacd92e4f25f45e110982a640c6e4933bb3.png | complex | <table><tr><td></td><td colspan="5">Fifths of observed vegetable intake</td><td></td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td><i>p</i>‐trendb</td></tr><tr><td>Total vegetables, g/day</td><td>≤ 82.8</td><td>>82.8 to ≤ 126.4</td><td>>126.4 to ≤ 182.1</td><td>&g... | <table><tr><td></td><td colspan="5">Fifths of observed vegetable intake</td><td></td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>p‐trendb</td></tr><tr><td>Total vegetables, g/day</td><td>≤ 82.8</td><td>>82.8 to ≤ 126.4</td><td>>126.4 to ≤ 182.1</td><td>>182.1 to ≤ 281.6</td><td>>281.7</td><t... | <table><tr><td>(95% CI)a</td><td>ef</td><td>0.99–1.14)</td><td>–1.12)</td><td>10)</td><td>–1.13)</td><td>.9</td></tr><tr><td>Tomatoes, g/day</td><td>≤ 9.0</td><td>>9.0 to ≤ 18.9</td><td>>18.9 to ≤ 30.8</td><td>>30.8 to ≤ 67.3</td><td>>67.3</td><td></td></tr><tr><td>Cases, n</td><td>1,612</td><td>1,540</td><td>1,443</td... |
06266bc210d3ed9f03982b1082ed027c6caf8518bf5f30851d755d920a9bddc8.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2"></td><td colspan="4">AA component</td><td colspan="4">Liquid crystal component</td></tr><tr><td>Compound</td><td>X<sub>M</sub></td><td>A<sub>0</sub>/nm<sup>2</sup></td><td>A<sub>C</sub>/nm<sup>2</sup></td><td>π<sub>C</sub>/mN·m<sup>−1</sup></td><td>C<sub>S... | <table><tr><td rowspan="2"></td><td rowspan="2"></td><td colspan="4">AA component</td><td colspan="4">Liquid crystal component</td><td colspan="2"></td></tr><tr><td>Compound</td><td>XM</td><td>A0/nm2</td><td>AC/nm2</td><td>πC/mN·m−1</td><td>CS′/m·N−1</td><td>A0/nm2</td><td>AC/nm2</td><td>πC/mN·m−1</td><td>CS′/m·N−1</td... | <table><tr><td rowspan="6">N52/AA</td><td>1</td><td>.20</td><td>.16</td><td>26.0</td><td></td><td>0.24</td><td></td><td>.5</td><td></td><td rowspan="18" colspan="2"></td></tr><tr><td>0.2</td><td>0.17</td><td>0.14</td><td>26.1</td><td>9.9</td><td>0.25</td><td>0.23</td><td>7.7</td><td>10.3</td></tr><tr><td>0.3</td><td>0.... |
5969e715b2f8ef90f0e8df6079dbb270794e68fb03688ca30ab563a648f4250d.png | simple | <table><tr><td></td><td>CKD Patients(<i>N</i> = 201)</td><td>Non-CKD(<i>N</i> = 201)</td><td><i>P</i>-value</td></tr><tr><td>Age, years</td><td>55.9 ± 9.9</td><td>52.5 ± 10.0</td><td>< 0.001</td></tr><tr><td>Male, %</td><td>55.2</td><td>45.3</td><td>0.06</td></tr><tr><td>African-American, %</td><td>60.7</t... | <table><tr><td></td><td>CKD Patients(N = 201)</td><td>Non-CKD(N = 201)</td><td>P-value</td></tr><tr><td>Age, years</td><td>55.9 ± 9.9</td><td>52.5 ± 10.0</td><td>< 0.001</td></tr><tr><td>Male, %</td><td>55.2</td><td>45.3</td><td>0.06</td></tr><tr><td>African-American, %</td><td>60.7</td><td>51.2</td><td>0.06</td></tr><... | <table><tr><td>Use of aspirin, %</td><td>34.8</td><td>8.5</td><td>< 0.001</td></tr><tr><td>BMI, kg/m2</td><td>32.2 ± 7.8</td><td>28.9 ± 6.4</td><td>< 0.001</td></tr><tr><td>Systolic BP, mm Hg</td><td>132.2 ± 21.0</td><td>122.0 ± 14.7</td><td>< 0.001</td></tr><tr><td>Diastolic BP, mm Hg</td><td>77.2 ± 13.5</td><td>77.6 ... |
8f288a4dd63e310d3d55d4d4ce7e14729e7ad3749f240c5b4878034f864cfb48.png | simple | <table><tr><td>Percentage of practice that reflects use of guidelines by referrers</td><td>Number of responses</td><td>Percentage of respondents</td></tr><tr><td><20%</td><td>2</td><td>4%</td></tr><tr><td>20–39%</td><td>5</td><td>7%</td></tr><tr><td>40–59%</td><td>10</td><td>4%</td></tr><tr><td>60–... | <table><tr><td>Percentage of practice that reflects use of guidelines by referrers</td><td>Number of responses</td><td>Percentage of respondents</td></tr><tr><td><20%</td><td>2</td><td>4%</td></tr><tr><td>20–39%</td><td>5</td><td>7%</td></tr></table> | <table><tr><td>40–59%</td><td>10</td><td>4%</td></tr><tr><td>60–79%</td><td>12</td><td>22%</td></tr><tr><td>80–100%</td><td>26</td><td>47%</td></tr></table> |
e3334be629e1145bdcb33aaac8dd0aa83849c4ecf964974bad083786d8efda91.png | complex | <table><tr><td>Term</td><td>Definition</td></tr><tr><td>Energy</td><td>A property of the matter expressed in calories; 1 Calorie (kcal) is the energy needed to increase the temperature of 1 kg of water by 1 °C.</td></tr><tr><td>Energy expenditure (EE)</td><td>Sum of internal heat produced (endogenous energy produc... | <table><tr><td>Term</td><td>Definition</td></tr><tr><td>Energy</td><td>A property of the matter expressed in calories; 1 Calorie (kcal) is the energy needed to increase the temperature of 1 kg of water by 1 °C.</td></tr><tr><td>Energy expenditure (EE)</td><td>Sum of internal heat produced (endogenous energy production)... | <table><tr><td>- Late</td><td>Beyond the first week in the ICU</td></tr></table> |
af6af78ab22f5475ab4edfc657e856813edb1faa12bdce8cae48c6ff110617d1.png | complex | <table><tr><td>Vitamin B12 Intake</td><td colspan="2">Model 1 (Unadjusted)</td><td colspan="2">Model 2 (Adjusted)</td></tr><tr><td>Total (μg/day)</td><td><148 pmol/L (<i>n</i> = 125)</td><td><i>p</i></td><td><148 pmol/L (<i>n</i> = 125)</td><td><i>p</i></td></tr><tr><td><1.87</td><td>1.00 (ref.)</td><td>-... | <table><tr><td>Vitamin B12 Intake</td><td colspan="2">Model 1 (Unadjusted)</td><td colspan="2">Model 2 (Adjusted)</td></tr><tr><td>Total (μg/day)</td><td><148 pmol/L (n = 125)</td><td>p</td><td><148 pmol/L (n = 125)</td><td>p</td></tr><tr><td><1.87</td><td>1.00 (ref.)</td><td>-</td><td>1.00 (ref.)</td><td>-</td></tr><t... | <table><tr><td>Vitamin B12 Intake</td><td colspan="2">Model 1 (Unadjusted)</td><td colspan="2">Model 2 (Adjusted)</td></tr><tr><td>>0.88</td><td>0.58 (0.31, 1.08)</td><td>0.086</td><td>0.49 (0.24, 1.01)</td><td>0.054</td></tr></table> |
7c2359b885af4b4ec0b67253f4bc4bcd24dec3301ed1c54854830f0f3bacc36a.png | simple | <table><tr><td>Treatment provider</td><td>No of consenting patients</td><td>Complications following tooth extractions</td><td>Complications following other treatment</td></tr><tr><td>Dental Hospital</td><td>3</td><td>0</td><td>0</td></tr><tr><td>Foundation Trust</td><td>9</td><td>1</td><td>1</td></tr><tr><td>District G... | <table><tr><td>Treatment provider</td><td>No of consenting patients</td><td>Complications following tooth extractions</td><td>Complications following other treatment</td></tr><tr><td>Dental Hospital</td><td>3</td><td>0</td><td>0</td></tr><tr><td>Foundation Trust</td><td>9</td><td>1</td><td>1</td></tr><tr><td>District G... | <table><tr><td>Treatment provider</td><td>No of consenting patients</td><td>Complications following tooth extractions</td><td>Complications following other treatment</td></tr><tr><td>Primary Care Oral Surgery</td><td>97</td><td>4</td><td>0</td></tr></table> |
f5fda0be3789c34169793cfae3a1395f4094e52b4c94cf94b49beef7be88a369.png | complex | <table><tr><td rowspan="2" colspan="2"> </td><td colspan="5">Diabetes model</td></tr><tr><td colspan="5">(High-fat feeding with low dose STZ)</td></tr><tr><td> </td><td>Control</td><td>0 mg/kg</td><td>15 mg/kg</td><td>20 mg/kg</td><td>25 mg/kg</td><td>30 mg/kg</td></tr><tr><td>Glucose (mmol/l)</td><td>12.7 ± 0.3</... | <table><tr><td rowspan="2" colspan="2"></td><td colspan="5">Diabetes model</td></tr><tr><td colspan="5">(High-fat feeding with low dose STZ)</td></tr><tr><td></td><td>Control</td><td>0 mg/kg</td><td>15 mg/kg</td><td>20 mg/kg</td><td>25 mg/kg</td><td>30 mg/kg</td></tr><tr><td>Glucose (mmol/l)</td><td>12.7 ± 0.3</td><td>... | <table><tr><td>esterol (mmol/l)</td><td>46 ± 0.13</td><td>1</td><td></td><td>± 0.27</td><td>± 0.58 *$</td><td>.02 ± 0.44 €</td></tr></table> |
399641955646694ea9047023a5bc8585a78be185fc8cc23d6437ebef00255ffc.png | complex | <table><tr><td rowspan="2">Recognition of</td><td colspan="3">Responses</td><td rowspan="2">Total number of participants that responded</td></tr><tr><td>Yes, <i>n</i> (%)</td><td>No, <i>n</i> (%)</td><td>Don't know, <i>n</i> (%)</td></tr><tr><td colspan="5">1. Cervical cancer risk factors</td></tr><tr><td>Early onset o... | <table><tr><td rowspan="2">Recognition of</td><td colspan="3">Responses</td><td rowspan="2">Total number of participants that responded</td></tr><tr><td>Yes, n (%)</td><td>No, n (%)</td><td>Don't know, n (%)</td></tr><tr><td colspan="5">1. Cervical cancer risk factors</td></tr><tr><td>Early onset of sexual activity</td... | <table><tr><td>Multiple male sexual partners</td><td>378 (88.3)</td><td>45 (10.5)</td><td>5 (1.2)</td><td>428</td></tr><tr><td>Smoking cigarettes/tobacco</td><td>203 (48.6)</td><td>182 (43.5)</td><td>33 (7.9)</td><td>418</td></tr><tr><td>Grand multiparity</td><td>195 (48.6)</td><td>181 (45.2)</td><td>25 (6.2)</td><td>4... |
0492946120b720d72f5c02c58b4d801c25903ae8923a3bba96b64d2f6dfc1643.png | complex | <table><tr><td>Sample</td><td colspan="2">Plaque samples</td><td colspan="2">Saliva samples</td></tr><tr><td></td><td>Day 1</td><td>Day 22</td><td>Day 1</td><td>Day 22</td></tr><tr><td>Dexolac 2</td><td>45,167 ± 8,156</td><td>66,500 ± 7,914</td><td>21,167 ± 4,019</td><td>31,667 ± 3,601</td></tr><tr>... | <table><tr><td>Sample</td><td colspan="2">Plaque samples</td><td colspan="2">Saliva samples</td></tr><tr><td></td><td>Day 1</td><td>Day 22</td><td>Day 1</td><td>Day 22</td></tr><tr><td>Dexolac 2</td><td>45,167 ± 8,156</td><td>66,500 ± 7,914</td><td>21,167 ± 4,019</td><td>31,667 ± 3,601</td></tr><tr><td>Lactodex 2</td><... | <table><tr><td>Sample</td><td colspan="2">Plaque samples</td><td colspan="2">Saliva samples</td></tr><tr><td></td><td>Day 1</td><td>Day 22</td><td>Day 1</td><td>Day 22</td></tr><tr><td>Lactogen 3</td><td>48,615 ± 6,449</td><td>69,231 ± 6,906</td><td>23,154 ± 3,105</td><td>33,154 ± 3,716</td></tr></table> |
23a23555de99931da56bffc5cf4b836bf4be61f63464ecf69d8340ce640f777f.png | simple | <table><tr><td>Variants</td><td>Clinical significance</td><td>Number of samples</td></tr><tr><td>BRCA1 c.5266dupC</td><td>Pathogenic</td><td>2</td></tr><tr><td>BRAC1 c.5095C>T</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA1 c.3916_3917del</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA2 c.6988A>G</td><td>V... | <table><tr><td>Variants</td><td>Clinical significance</td><td>Number of samples</td></tr></table> | <table><tr><td>BRCA1 c.5266dupC</td><td>Pathogenic</td><td>2</td></tr><tr><td>BRAC1 c.5095C>T</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA1 c.3916_3917del</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA2 c.6988A>G</td><td>VUS</td><td>1</td></tr><tr><td>BRCA2 c.8482A>G</td><td>VUS</td><td>1</td></tr><tr><td>BRC... |
a4c01a32819522abc80742fbc3d8966a67d7c52e93678c30c8dfeae0229fece0.png | complex | <table><tr><td rowspan="3">Antibacterial Result</td><td colspan="2">Gram-negative</td><td colspan="2">Gram-positive</td></tr><tr><td><i>E. coli</i>ATCC 25922</td><td><i>P. aeruginosa</i>ATCC 27853</td><td><i>S. aureus</i>ATCC 25923</td><td><i>B. subtilis</i>ATCC 6633</td></tr><tr><td>MIC (μg/mL)</td><td>64</td><td... | <table><tr><td rowspan="3">Antibacterial Result</td><td colspan="2">Gram-negative</td></tr><tr><td>E. coliATCC 25922</td><td>P. aeruginosaATCC 27853</td></tr><tr><td colspan="2"></td></tr><tr><td>MIC (μg/mL)</td><td>64</td><td>500</td></tr></table> | <table><tr><td colspan="2">Gram-positive</td></tr><tr><td>S. aureusATCC 25923</td><td>B. subtilisATCC 6633</td></tr><tr><td colspan="2"></td></tr><tr><td>32</td><td>16</td></tr></table> |
a53024c051b01ad96f55241f931636259df8ca0b4500761f8eb51ae7bd0e7f24.png | simple | <table><tr><td>Heating current of the emitter I (mA)</td><td>0.8</td><td>0.9</td><td>1.0</td><td>1.1</td></tr><tr><td>Steady temperature T (K)</td><td>316.3087</td><td>323.0872</td><td>330.387</td><td>339.1644</td></tr><tr><td>G<sub>con</sub> (W·K<sup>−1</sup>)</td><td>1.34 × 10<sup>−6</sup></td><... | <table><tr><td>Heating curren</td><td>0</td><td>0.9</td><td></td><td>1.</td></tr></table> | <table><tr><td>t of the emitter I (mA)</td><td>.8</td><td></td><td>1.0</td><td>1</td></tr><tr><td>Steady temperature T (K)</td><td>316.3087</td><td>323.0872</td><td>330.387</td><td>339.1644</td></tr><tr><td>Gcon (W·K−1)</td><td>1.34 × 10−6</td><td>1.33 × 10−6</td><td>1.32 × 10−6</td><td>1.31 × 10−6</td></tr><tr><td>Gfr... |
0f224a6ad3a655ef19bea4bde68a19bedfc357e12d12dddf59508fb2ce3bed00.png | simple | <table><tr><td>Items of the scale</td><td>Domains</td></tr><tr><td>1. I feel guilty because I have HIV.</td><td>Internalized stigma</td></tr><tr><td>2. People’s attitudes about HIV make me feel worse about myself.</td><td>Internalized stigma</td></tr><tr><td>3. People with HIV lose their jobs when their employers... | <table><tr><td>Items of the scale</td></tr><tr><td>1. I feel guilty because I have HIV.</td></tr><tr><td>2. People’s attitudes about HIV make me feel worse about myself.</td></tr><tr><td>3. People with HIV lose their jobs when their employers learn.</td></tr><tr><td>4. I feel I am not as good a person as others because... | <table><tr><td>Domains</td></tr><tr><td>Internalized stigma</td></tr><tr><td>Internalized stigma</td></tr><tr><td>Perceived stigma</td></tr><tr><td>Internalized stigma</td></tr><tr><td>Perceived stigma</td></tr><tr><td>Perceived stigma</td></tr><tr><td>Internalized stigma</td></tr><tr><td>Internalized stigma</td></tr><... |
54069fb6b161e8eeae56e6e41c7f8a3bc98a8b17bc695d75909e82f47d5d205b.png | simple | <table><tr><td>Name</td><td>Sequence 53</td></tr><tr><td>rmhS100 — F</td><td>ATgTCTTCCATCAgTATTCAggg</td></tr><tr><td>rmhS100 — R</td><td>TCTCCATCACTTTgTCCACC</td></tr><tr><td>rmhS100 — pr</td><td>[FAM] TCTTCAgCTTgTgCTTgTCACCCT [BH1]</td></tr><tr><td>Pmp22 — TM — S</td><td>gTgCTAgTgTTgCTCT... | <table><tr><td>Name</td><td>Sequence 53</td></tr><tr><td>rmhS100 — F</td><td>ATgTCTTCCATCAgTATTCAggg</td></tr><tr><td>rmhS100 — R</td><td>TCTCCATCACTTTgTCCACC</td></tr><tr><td>rmhS100 — pr</td><td>[FAM] TCTTCAgCTTgTgCTTgTCACCCT [BH1]</td></tr><tr><td>Pmp22 — TM — S</td><td>gTgCTAgTgTTgCTCTTC</td></tr><tr><td>Pmp22 — TM... | <table><tr><td>Name</td><td>Sequence 53</td></tr><tr><td>rPmp2 — TM — A</td><td>TCCAgCAACTTTCTCTTTA</td></tr><tr><td>Pmp2 — TMpr</td><td>[FAM] CCACTTCTgCACTTgCTTCA [BH1]</td></tr><tr><td>rmh18S — TMF</td><td>gCCgCTAgAggTgAAATTCTTg</td></tr><tr><td>rmh18S — TMR</td><td>CATTCTTggCAAATgCTTTCg</td></tr><tr><td>rmh18S TMpr<... |
08847966fd5d950bc11e6c5ac51df23053b6228f25343a6e161d2d9f8d3958ea.png | complex | <table><tr><td> </td><td colspan="4">Follow up</td></tr><tr><td>Type of intervention</td><td>3 months</td><td>6 months</td><td>1 year</td><td>5 years</td></tr><tr><td>2</td><td>6 [−9.8; 21.8]</td><td>6.2 [−9.1; 21.4]</td><td>6.6 [−7.7; 20.8]</td><td>9.7 [−2.1; 21.5]</td></tr><tr><td>3</td><td>&#... | <table><tr><td></td><td colspan="4">Follow up</td></tr></table> | <table><tr><td>Type of intervention</td><td>3 months</td><td>6 months</td><td>1 year</td><td>5 years</td></tr><tr><td>2</td><td>6 [−9.8; 21.8]</td><td>6.2 [−9.1; 21.4]</td><td>6.6 [−7.7; 20.8]</td><td>9.7 [−2.1; 21.5]</td></tr><tr><td>3</td><td>−11.8 [−19.6; −3.9]</td><td>−11.3 [−19; −3.6]</td><td>−10.4 [−17.7; −3.1]</... |
5bab5b15458afb303913d4fbc30298251601900471fae81837ea78ac10a41ee0.png | simple | <table><tr><td>GroupsParameters</td><td>Vitamin D ≤ 12.5 (nmol/l)</td><td>12.5<vitamin D ≤ 25</td><td>25<vitamin D ≤ 35</td><td>35.1<vitamin D ≤ 150</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>27.32 ± 5.02</td><td>26.44 ± 4.52</td><td>27.66 ± 5.16</td><td>26.99 ±... | <table><tr><td>GroupsParameters</td><td>Vitamin D ≤ 12.5 (nmol/l)</td><td>12.5<vitamin D ≤ 25</td><td>25<vitamin D ≤ 35</td><td>35.1<vitamin D ≤ 150</td></tr></table> | <table><tr><td>BMI (kg/m2)</td><td>27.32 ± 5.02</td><td>26.44 ± 4.52</td><td>27.66 ± 5.16</td><td>26.99 ± 4.93</td></tr><tr><td>Calcium intake (mg/day)</td><td>503.39 ± 303.1*</td><td>577.93 ± 304.9*</td><td>595.84 ± 313.6*</td><td>714.67 ± 330.8</td></tr></table> |
bde67b9996c977b364a70349f2c50cdfcb2c957cbcf81176f44a7fe0ce888bd5.png | simple | <table><tr><td>Characteristic</td><td>Cases (<i>n</i> = 300)</td><td>Controls (<i>n</i> = 299)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>57.9 (5.2)</td><td>57.8 (5.2)</td><td>0.82</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>26.0 (3.3)</td><td>26.5 (3.6)</td><td>0.10</td></tr><tr><td>Cigarett... | <table><tr><td>Characteristic</td><td>Cases (n = 300)</td><td>Controls (n = 299)</td><td>P</td></tr><tr><td>Age (years)</td><td>57.9 (5.2)</td><td>57.8 (5.2)</td><td>0.82</td></tr><tr><td>Body mass index (kg/m2)</td><td>26.0 (3.3)</td><td>26.5 (3.6)</td><td>0.10</td></tr><tr><td>Cigarettes per day</td><td>19.2 (8.9)</t... | <table><tr><td>Characteristic</td><td>Cases (n = 300)</td><td>Controls (n = 299)</td><td>P</td></tr><tr><td>Fruit and vegetable intake (g/d)2</td><td>242 (132)</td><td>241 (128)</td><td>0.94</td></tr><tr><td>β-Carotene intake (μg/d)2</td><td>2097 (1382)</td><td>2044 (1333)</td><td>0.62</td></tr><tr><td>Total dairy prod... |
b84148f7a0a6b5f89f3aaeb9bc98407fb55df748e62a1513a9da4fb0af63f571.png | complex | <table><tr><td> </td><td>Identifiable (n = 296)† n (%)</td><td>Anonymous (n = 315) †† n (%)</td><td>Chi<sup>2</sup>statistic (degrees of freedom), P value</td><td>Odds ratio (95% confidence interval)</td><td>Adjusted* odds ratio (95% confidence interval)</td></tr><tr><td colspan="6">Barriers to Care</... | <table><tr><td></td><td>Identifiable (n = 296)† n (%)</td><td>Anonymous (n = 315) †† n (%)</td><td>Chi2statistic (degrees of freedom), P value</td><td>Odds ratio (95% confidence interval)</td><td>Adjusted* odds ratio (95% confidence interval)</td></tr><tr><td colspan="6">Barriers to Car</td></tr></table> | <table><tr><td colspan="6">e</td></tr><tr><td>It is difficult to schedule an appointment</td><td>66 (23.9)</td><td>63 (22.0)</td><td>0.31 (1), P = 0.580</td><td>0.89 (0.60-1.33)</td><td>0.95 (0.64-1.41)</td></tr><tr><td>It is difficult to get time off</td><td>86 (31.1)</td><td>108 (36.9)</td><td>2.14 (1), P = 0.143</td... |
88edc5795422cba7647ad8226617656e8ea03d4dd417e0a94618d1aff133fac3.png | simple | <table><tr><td>Biomarkera</td><td>Mean ± SD</td><td>Median (min/max)</td></tr><tr><td>IL-6 (pg/mL)</td><td>2.42 ± 1.85</td><td>1.92 (0.25/10.0)</td></tr><tr><td>TNF-α (pg/mL)b</td><td>1.92 ± 1.64</td><td>1.41 (0.5/14.3)</td></tr><tr><td>sTNF-RII (pg/mL)</td><td>3,610 ± 1,489</td><td>3,235 (657/... | <table><tr><td>Biomarkera</td><td>Mean ± SD</td></tr><tr><td>IL-6 (pg/mL)</td><td>2.42 ± 1.85</td></tr><tr><td>TNF-α (pg/mL)b</td><td>1.92 ± 1.64</td></tr><tr><td>sTNF-RII (pg/mL)</td><td>3,610 ± 1,489</td></tr><tr><td>sP-selectin (ng/mL)</td><td>45.0 ± 16.6</td></tr><tr><td>CRP (ng/mL)c</td><td>2,434 ± 3,181</td></tr>... | <table><tr><td>Median (min/max)</td></tr><tr><td>1.92 (0.25/10.0)</td></tr><tr><td>1.41 (0.5/14.3)</td></tr><tr><td>3,235 (657/11,584)</td></tr><tr><td>42.5 (6.0/119.9)</td></tr><tr><td>1,403 (250/26,799)</td></tr><tr><td>4,288 (669/13,138)</td></tr><tr><td>17.8 (5.5/50.7)</td></tr></table> |
a517a208330aecf7f827422111acdd958c66df9309fc98f8cc19516cf21a26b8.png | simple | <table><tr><td>permanent transect ID</td><td>latitude of origin (° N)</td><td>longitude of origin (° W)</td><td>elevation (m)</td><td>burn severity class</td><td>burn severity score</td><td>soil pH (± s.e.)</td></tr><tr><td>101</td><td>69.995</td><td>150.283</td><td>359</td><td>severe</td><td>1.8</td><td... | <table><tr><td>permanent transect ID</td><td>latitude of origin (° N)</td><td>longitude of origin (° W)</td><td>elevation (m)</td><td>burn severity class</td><td>burn severity score</td><td>soil pH (± s.e.)</td></tr><tr><td>101</td><td>69.995</td><td>150.283</td><td>359</td><td>severe</td><td>1.8</td><td>4.6 (0.18)</td... | <table><tr><td>permanent transect ID</td><td>latitude of origin (° N)</td><td>longitude of origin (° W)</td><td>elevation (m)</td><td>burn severity class</td><td>burn severity score</td><td>soil pH (± s.e.)</td></tr><tr><td>103</td><td>68.954</td><td>150.207</td><td>403</td><td>moderate</td><td>3.1</td><td>4.7 (0.05)</... |
21635569144ca2ce646973459a6f76ee0ea6ef2405fb48a0df877d88b5715b01.png | simple | <table><tr><td>Enzyme</td><td>Recognition site</td><td>Sensitivity to methylation</td></tr><tr><td>Aci I</td><td>5'-CCGC-3'</td><td>CpG</td></tr><tr><td>Bfa I</td><td>5'-CTAG-3'</td><td>none</td></tr><tr><td>BstU I</td><td>5'-CGCG-3'</td><td>CpG</td></tr><tr><td>Cfo I</td><td>5'-GCGC-3'</td><td>CpG</td></tr><tr><td>Hae... | <table><tr><td>Enzyme</td><td>Recognition site</td></tr><tr><td>Aci I</td><td>5'-CCGC-3'</td></tr><tr><td>Bfa I</td><td>5'-CTAG-3'</td></tr><tr><td>BstU I</td><td>5'-CGCG-3'</td></tr><tr><td>Cfo I</td><td>5'-GCGC-3'</td></tr><tr><td>Hae III</td><td>5'-GGCC-3'</td></tr><tr><td>MspI</td><td>5'-CCGG-3'</td></tr><tr><td>Sa... | <table><tr><td>Sensitivity to methylation</td></tr><tr><td>CpG</td></tr><tr><td>none</td></tr><tr><td>CpG</td></tr><tr><td>CpG</td></tr><tr><td>none</td></tr><tr><td>CpNpG</td></tr><tr><td>none</td></tr></table> |
f74ca4d46057baabdb4a5d50e2aebb74c2709c2dac7db39cad1eea105947bc3f.png | simple | <table><tr><td></td><td>Number of cases</td><td>Median (IQR) ng/mL</td></tr><tr><td>sAxl</td><td>1067</td><td></td></tr><tr><td> Healthy controls</td><td>75</td><td>40.15 (35.22 - 46.85)</td></tr><tr><td> Tumors patients:</td><td>402</td><td></td></tr><tr><td> All HCC</td><td>347*</td><td>78.69 (55.09 - 101.5)</td></tr... | <table><tr><td></td><td>Number of cases</td><td>Median (IQR) ng/mL</td></tr><tr><td>sAxl</td><td>1067</td><td></td></tr><tr><td>Healthy controls</td><td>75</td><td>40.15 (35.22 - 46.85)</td></tr><tr><td>Tumors patients:</td><td>402</td><td></td></tr><tr><td>All HCC</td><td>347*</td><td>78.69 (55.09 - 101.5)</td></tr><t... | <table><tr><td>All HCC</td><td>274</td><td>12.90 (5.275 - 173.3)</td></tr><tr><td>HCC with cirrhosis</td><td>194</td><td>11.50 (0 - 49.33)</td></tr><tr><td>HCC w/o cirrhosis</td><td>28</td><td>23.60 (3.900 - 4743)</td></tr><tr><td>F4 (cirrhosis w/o HCC)</td><td>24</td><td>4.65 (3.025 - 6.650)</td></tr></table> |
16a7d661818b7db32f9c2be04a6b38614f0c9fdf53ecf672d0a5a5e60ce59b5b.png | simple | <table><tr><td></td><td>Preoperative</td><td>6 months</td><td>12 months</td><td>18 months</td></tr><tr><td>Upper limb (<i>n</i>)</td><td>15</td><td>12</td><td>7</td><td>1</td></tr><tr><td> L-Dex [mean (range)]</td><td>41.2 (18–75)</td><td>35.3 (14–49)</td><td>25.1 (13–45)</td><td>27</td></tr><tr><td> ... | <table><tr><td></td><td>Preoperative</td><td>6 months</td></tr><tr><td>Upper limb (n)</td><td>15</td><td>12</td></tr><tr><td>L-Dex [mean (range)]</td><td>41.2 (18–75)</td><td>35.3 (14–49)</td></tr><tr><td>Significance</td><td>–</td><td>p = 0.068</td></tr><tr><td>Mean excess volume [ml (range)]</td><td>1139.5 (645–1755)... | <table><tr><td>12 months</td><td>18 months</td></tr><tr><td>7</td><td>1</td></tr><tr><td>25.1 (13–45)</td><td>27</td></tr><tr><td>p = 0.018</td><td>–</td></tr><tr><td>18.7 (−244 to 218)</td><td>−339a</td></tr><tr><td>1.3 (−5 to 8)</td><td>−11a</td></tr><tr><td>p = 0.001</td><td>–</td></tr><tr><td>1</td><td>0</td></tr><... |
5ab0ab02c0603ec6c52f8847b70d24798d0b222a583d00b5039307143820d465.png | simple | <table><tr><td>Samples</td><td>Vitamin A</td><td>Vitamin B<sub>2</sub></td><td>Vitamin B<sub>3</sub></td><td>Vitamin C</td></tr><tr><td>Control</td><td>0.01</td><td>0.01</td><td>0.05</td><td>62.54</td></tr><tr><td>A</td><td>1.98</td><td>30.25</td><td>0.18</td><td>40.72</td></tr><tr><td>B</td><td>2.00</td><td>25.42</td>... | <table><tr><td>Samples</td><td>Vitamin A</td><td>Vitamin B2</td><td>Vitamin B3</td><td>Vitamin C</td></tr></table> | <table><tr><td>Control</td><td>0.01</td><td>0.01</td><td>0.05</td><td>62.54</td></tr><tr><td>A</td><td>1.98</td><td>30.25</td><td>0.18</td><td>40.72</td></tr><tr><td>B</td><td>2.00</td><td>25.42</td><td>0.15</td><td>34.12</td></tr><tr><td>C</td><td>2.20</td><td>22.12</td><td>0.15</td><td>30.56</td></tr><tr><td>D</td><t... |
5acc5abe3ebb741c1a2fd6fe8853b675cec299b7d1ab04ebeddef48fed0a3852.png | complex | <table><tr><td>Sex</td><td>Woman</td></tr><tr><td>Age</td><td>33 years</td></tr><tr><td colspan="2">EPILEPSY</td></tr><tr><td>Brain insult</td><td>TBI when she was 1 year old</td></tr><tr><td>Febrile seizure</td><td>No</td></tr><tr><td>First epileptic seizure</td><td>9 years old</td></tr><tr><td>Age of onset Auras</td>... | <table><tr><td>Sex</td><td>Woman</td></tr><tr><td>Age</td><td>33 years</td></tr><tr><td colspan="2">EPILEPSY</td></tr><tr><td>Brain insult</td><td>TBI when she was 1 year old</td></tr><tr><td>Febrile seizure</td><td>No</td></tr><tr><td>First epileptic seizure</td><td>9 years old</td></tr><tr><td>Age of onset Auras</td>... | <table><tr><td>ncy</td><td>uster/4–5 month</td></tr><tr><td>Complex partial seizures</td><td>Yes</td></tr><tr><td>Antiepileptic treatment</td><td>Trileptal, Keppra, Noiafren and Stilnox</td></tr><tr><td>Neurological examination</td><td>Normal</td></tr><tr><td>Ictal EEG</td><td>Video EEG predominance interictal activity... |
3bf776b13e660a500fa695cebd45256e528fe83aeeeacdc9c40389c34a4569b1.png | complex | <table><tr><td>Variables</td><td colspan="2">Screening phase (<i>n</i> = 30)</td><td colspan="2">Training cohort (<i>n</i> = 84)</td><td colspan="2">Testing cohort (<i>n</i> = 214)</td><td colspan="2">Additional validation cohort (<i>n</i> = 99)</td></tr><tr><td></td><td>Cases (%)</td><td>Controls (%)</td><td>Cases (%)... | <table><tr><td>Variables</td><td colspan="2">Screening phase (n = 30)</td><td colspan="2">Training cohort (n = 84)</td><td colspan="2">Testing cohort (n = 214)</td><td colspan="2">Additional validation cohort (n = 99)</td></tr><tr><td></td><td>Cases (%)</td><td>Controls (%)</td><td>Cases (%)</td><td>Controls (%)</td><t... | <table><tr><td>Variables</td><td colspan="2">Screening phase (n = 30)</td><td colspan="2">Training cohort (n = 84)</td><td colspan="2">Testing cohort (n = 214)</td><td colspan="2">Additional validation cohort (n = 99)</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></... |
a73e87a17d18e2059830090b0242d7bd63d7002ea73595c75d798cbb0b56b982.png | simple | <table><tr><td>Lane</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1</td><td>1.00</td><td>0.72</td><td>0.37</td></tr><tr><td>2</td><td>0.72</td><td>1.00</td><td>0.45</td></tr><tr><td>3</td><td>0.37</td><td>0.45</td><td>1.00</td></tr></table> | <table><tr><td>Lane</td><td>1</td><td>2</td><td>3</td></tr><tr><td></td><td>1.0</td><td>0.7</td><td>0.37</td></tr></table> | <table><tr><td>Lane</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1</td><td>0</td><td>2</td><td></td></tr><tr><td>2</td><td>0.72</td><td>1.00</td><td>0.45</td></tr><tr><td>3</td><td>0.37</td><td>0.45</td><td>1.00</td></tr></table> |
4612e4f90beb0d0ea59043ed20e9f05a566b0b7ff39872659ad3719627092802.png | simple | <table><tr><td></td><td>Arthritic patient volunteers (n = 13)</td><td>Healthy volunteers (n = 18)</td></tr><tr><td>Age (y)*</td><td>64.8 (6.4)</td><td>33.8 (7.9)</td></tr><tr><td>Body mass index*, kg/m<sup>2</sup></td><td>36.1 (5.4)</td><td>23.3 (3.0)</td></tr><tr><td>Male, n</td><td>7</td><td>6</td></tr></table> | <table><tr><td></td><td>Arthritic patient volunteers (n = 13)</td><td>Healthy volunteers (n = 18)</td></tr></table> | <table><tr><td>Age (y)*</td><td>64.8 (6.4)</td><td>33.8 (7.9)</td></tr><tr><td>Body mass index*, kg/m2</td><td>36.1 (5.4)</td><td>23.3 (3.0)</td></tr><tr><td>Male, n</td><td>7</td><td>6</td></tr></table> |
41cf081761f09bb5fa731e604bce5844abbf289625365a32c21ed1820b1da852.png | simple | <table><tr><td>Category</td><td><i>P</i> value</td><td>Total occurrence</td></tr><tr><td>Multicellular organismal process</td><td>7.36E−09</td><td>1048</td></tr><tr><td>Biological adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Cell adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Oxidati... | <table><tr><td>Category</td><td>P value</td><td>Total occurrence</td></tr><tr><td>Multicellular organismal process</td><td>7.36E−09</td><td>1048</td></tr><tr><td>Biological adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Cell adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Oxidation reduction</td><td>9.32... | <table><tr><td>Regulation of multicellular organismal process</td><td>2.94E−05</td><td>358</td></tr><tr><td>Developmental process</td><td>3.21E−05</td><td>1756</td></tr><tr><td>Cellular ion homeostasis</td><td>4.49E−05</td><td>117</td></tr><tr><td>Branching morphogenesis of a tube</td><td>5.10E−05</td><td>40</td></tr><... |
7e2ae4f3e54708b541644fb29f8fb4e1b2ea4a1f2ac75bfcfcbe596b3628d2e0.png | simple | <table><tr><td>Clinical parameters</td><td>Case(n =124 )</td></tr><tr><td>Incidence rate , per 100 person-years</td><td>5.4</td></tr><tr><td>Median (IQR), duration from starting ARV to hepatitis, years</td><td>1.3(0.5–3.5)</td></tr><tr><td>Mean ALT level at time of ALT elevation, IU/L (±SD)</td><td>73 ±... | <table><tr><td>Clinical parameters</td><td>Case(n =124 )</td></tr><tr><td>Incidence rate , per 100 person-years</td><td>5.4</td></tr><tr><td>Median (IQR), duration from starting ARV to hepatitis, years</td><td>1.3(0.5–3.5)</td></tr><tr><td>Mean ALT level at time of ALT elevation, IU/L (±SD)</td><td>73 ± 107</td></tr><t... | <table><tr><td>o Weight loss</td><td>4(3.2)</td></tr><tr><td>o Jaundice</td><td>1(0.8)</td></tr><tr><td>o Liver tenderness</td><td>1(0.8)</td></tr></table> |
df7aaecac6a9589e624cd0fc7b224437e5fe9314e399bcec2978a9011a34db84.png | complex | <table><tr><td>Characteristics</td><td colspan="2">Physicians (<i>N</i> = 55)</td><td colspan="2">Nurses (<i>N</i> = 78)</td><td><i>p</i></td><td colspan="2">Total (<i>N</i> = 133)</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td></td><td>n</td><td>%</td></tr><tr><td colspan="8">Gender</td></tr><tr><td... | <table><tr><td>Characteristics</td><td colspan="2">Physicians (N = 55)</td><td colspan="2">Nurses (N = 78)</td><td>p</td><td colspan="2">Total (N = 133)</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td></td><td>n</td><td>%</td></tr><tr><td colspan="8">Gender</td></tr><tr><td>- Male</td><td>35</td><td>6... | <table><tr><td colspan="8">Marital status</td></tr><tr><td>- Married or Cohabiting</td><td>34</td><td>61.8</td><td>54</td><td>69.2</td><td rowspan="3">0.094</td><td>88</td><td>66.2</td></tr><tr><td>- Single</td><td>21</td><td>38.2</td><td>20</td><td>25.6</td><td>41</td><td>30.8</td></tr><tr><td>- Widow/divorced/separat... |
454f5688740a8e515c79c2d789f5d68780c01cf2e5afec7bff734a74c766d308.png | complex | <table><tr><td></td><td colspan="2">ypT0</td><td colspan="2">ypT1</td><td colspan="2">ypT2</td><td colspan="2">ypT3–4</td></tr><tr><td>Variable</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td colspan="9">Sex</td></tr><tr><td> Male</td><td>74</td><td>64.9</td><td>69... | <table><tr><td></td><td colspan="2">ypT0</td><td colspan="2">ypT1</td><td colspan="2">ypT2</td><td colspan="2">ypT3–4</td></tr><tr><td>Variable</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>Male</td><td>74</td><td>64.9</td><td>692</td><... | <table><tr><td>Black</td><td>8</td><td>7</td><td>97</td><td>8.9</td><td>188</td><td>9.5</td><td>729</td><td>7.7</td></tr><tr><td>Other</td><td>7</td><td>6.2</td><td>84</td><td>7.7</td><td>197</td><td>9.9</td><td>995</td><td>10.5</td></tr><tr><td colspan="9">Pathological grading</td></tr><tr><td>Grade I</td><td>12</td><... |
641fc238c42e8acddc74144eb958123f7134ab8811a0b00df80d6fb7596dba78.png | simple | <table><tr><td></td><td>Unit</td><td></td></tr><tr><td>Male:female</td><td><i>n</i> (%)</td><td>11 (26.2):31 (73.8)</td></tr><tr><td>Age</td><td>years</td><td>37 ± 12 (24–63)</td></tr><tr><td>Weight</td><td>kg</td><td>70.3 ± 11.5</td></tr><tr><td>BMI</td><td>kg/m<sup>2</sup></td><td>23.9 ± 3.1 (19.... | <table><tr><td></td><td>Unit</td></tr><tr><td>Male:female</td><td>n (%)</td></tr><tr><td>Age</td><td>years</td></tr><tr><td>Weight</td><td>kg</td></tr><tr><td>BMI</td><td>kg/m2</td></tr><tr><td>Current smoker</td><td>n (%)</td></tr><tr><td>Nutrition</td><td>n (%)</td></tr><tr><td>Meat-based</td><td></td></tr><tr><td>Fl... | <table><tr><td></td></tr><tr><td>11 (26.2):31 (73.8)</td></tr><tr><td>37 ± 12 (24–63)</td></tr><tr><td>70.3 ± 11.5</td></tr><tr><td>23.9 ± 3.1 (19.0–30.4)</td></tr><tr><td>2 (4.8)</td></tr><tr><td></td></tr><tr><td>37 (88.1)</td></tr><tr><td>5 (11.9)</td></tr><tr><td></td></tr><tr><td>5 (11.9)</td></tr><tr><td>2 (4.8)<... |
9f512f54220e8a2e655d2525c8a2b1a593165cdb379efce4b809e5148a59538d.png | complex | <table><tr><td rowspan="2">Follow up</td><td>1wk</td><td colspan="2">2 m</td><td colspan="2">6 m</td></tr><tr><td>CCC size</td><td>CCC size</td><td>Change from 1 week(percentage)</td><td>CCC size</td><td>Change from 2 months(percentage)</td></tr><tr><td>Precizon (IOL A)</td><td>20.69 ± 1.50</td><td>17.17 ± 3.... | <table><tr><td></td><td>1w</td><td colspan="2"></td><td colspan="2">6</td></tr></table> | <table><tr><td rowspan="2">Follow up</td><td>k</td><td colspan="2">2 m</td><td colspan="2"> m</td></tr><tr><td>CCC size</td><td>CCC size</td><td>Change from 1 week(percentage)</td><td>CCC size</td><td>Change from 2 months(percentage)</td></tr><tr><td>Precizon (IOL A)</td><td>20.69 ± 1.50</td><td>17.17 ± 3.23</td><td>−3... |
17d3bee20e337b3138c685664052f32ace7de708c320fe8097a40cae6d26a585.png | simple | <table><tr><td>Drug(concentration)</td><td>Skin prick test(dilution factor)</td><td>Intradermal test(dilution factor)</td></tr><tr><td>Midazolam (5 mg/ml)</td><td>5 mg/ml (pure)</td><td>0.5 mg/ml (1:10)</td></tr><tr><td>Propofol (10 mg/ml)</td><td>10 mg/ml (pure)</td><td>1 mg/ml (1:10)</td></tr><tr><td>Ketamine (10 mg/... | <table><tr><td>Drug(concentration)</td><td>Skin prick test(dilution factor)</td></tr><tr><td>Midazolam (5 mg/ml)</td><td>5 mg/ml (pure)</td></tr><tr><td>Propofol (10 mg/ml)</td><td>10 mg/ml (pure)</td></tr><tr><td>Ketamine (10 mg/ml)</td><td>10 mg/ml (pure)</td></tr><tr><td>Thiopental (25 mg/ml)</td><td>25 mg/ml (pure)... | <table><tr><td>Intradermal test(dilution factor)</td></tr><tr><td>0.5 mg/ml (1:10)</td></tr><tr><td>1 mg/ml (1:10)</td></tr><tr><td>1 mg/ml (1:10)</td></tr><tr><td>2.5 mg/ml (1:10)</td></tr><tr><td>0.2 mg/ml (1:10)</td></tr><tr><td>0.01 mg/ml (1:1000)</td></tr><tr><td>0.005 mg/ml (1:10)</td></tr><tr><td>0.005 mg/ml (1:... |
06a4316a9ba4c5e3150589b5b3d37eddc91cff1ec0f875dc3ab5b2d2025979cf.png | simple | <table><tr><td>Child</td><td>Deficiency of the limb</td><td>Associated anomaly</td><td>Relation of the relative</td><td>Limb anomaly of the relative</td></tr><tr><td>1</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>2</td><td>split hand of right upper limb</td... | <table><tr><td>Child</td><td>Deficiency of the limb</td><td>Associated anomaly</td><td>Relation of the relative</td><td>Limb anomaly of the relative</td></tr><tr><td>1</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>2</td><td>split hand of right upper limb</td... | <table><tr><td>4</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>5</td><td>split hand of both upper limbs and split foot of both lower limbs</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>6</td><td>radial deficiency of left upper limb</td... |
3cb9e729529a4121b1fc4709b36d859fc5f030074aeb90b9aa711d5512249e0d.png | simple | <table><tr><td>Genus (family)</td><td>Order/suborder</td><td>Organelle genome</td><td>Inheritance</td><td>Reference</td></tr><tr><td><i>Equisetum</i> (Equisetaceae)</td><td>Equisetales</td><td>Plastome</td><td>Maternal</td><td>Guillon and Raquin, 2000</td></tr><tr><td><i>Ceratopteris</i> (Pteridaceae)</td><td>Polypodia... | <table><tr><td>Genus (family)</td><td>Order/suborder</td><td>Organelle genome</td><td>Inheritance</td><td>Reference</td></tr><tr><td>Equisetum (Equisetaceae)</td><td>Equisetales</td><td>Plastome</td><td>Maternal</td><td>Guillon and Raquin, 2000</td></tr><tr><td>Ceratopteris (Pteridaceae)</td><td>Polypodiales/Pteridinea... | <table><tr><td>Asplenium (Aspleniaceae)</td><td>Polypodiales/Aspleniineae</td><td>Plastome</td><td>Maternal</td><td>Vogel et al., 1997</td></tr><tr><td>Deparia (Athyriaceae)</td><td>Polypodiales/Aspleniineae</td><td>Plastome and mitogenome</td><td>Maternal</td><td>This study</td></tr></table> |
c2d61879219a1e6484f6f4208fa6230cf9a78c2f5a4971dd04e38b0848f5ddbc.png | simple | <table><tr><td>Date</td><td>Event</td></tr><tr><td>28 to 31 Oct 2008</td><td>Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)</td></tr><tr><td>9 to 10 Jul 2009</td><td>Sixth Session of the IGBC (Paris)</td></tr><tr><td>23 to 25 Nov 2009</td><td>Sixteenth Session of the IBC (Mexi... | <table><tr><td>Date</td><td>Event</td></tr><tr><td>28 to 31 Oct 2008</td><td>Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)</td></tr><tr><td>9 to 10 Jul 2009</td><td>Sixth Session of the IGBC (Paris)</td></tr><tr><td>23 t</td><td>Sixteenth Session of the IBC </td></tr></table> | <table><tr><td>o 25 Nov 2009</td><td>(Mexico City)</td></tr><tr><td>26 to 29 Oct 2010</td><td>Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris)</td></tr><tr><td>31 May to 2 Jun 2011</td><td>Eighteenth Session of the IBC* (Baku)</td></tr><tr><td>5 to 6 Sep 2011</td><td>Sevent... |
2dc1de5cf318b597870763b6c821206bf50a132cbc639ad9d29d9739b84720b4.png | complex | <table><tr><td><i>PredictiveVariables</i></td><td><i>HR</i></td><td><i>CI</i></td><td><i>P</i></td></tr><tr><td><i>Cyclin D1</i></td><td>10.864</td><td>1.055 – 86.250</td><td>0.03*</td></tr><tr><td> (baseline < 6.1)</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>Cyclin A</i></td><td>13.886</td><td>1.012 ... | <table><tr><td>PredictiveVariables</td><td>HR</td><td>CI</td><td>P</td></tr><tr><td>Cyclin D1</td><td>10.864</td><td>1.055 – 86.250</td><td>0.03*</td></tr><tr><td>(baseline < 6.1)</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Cyclin A</td><td>13.886</td><td>1.012 – 190.579</td><td>0.0490*</td></tr></table> | <table><tr><td>PredictiveVariables</td><td>HR</td><td>CI</td><td>P</td></tr><tr><td>(baseline < 10.5)</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Positive Lymph node metastasis</td><td>3.921</td><td>1.057 – 14.472</td><td>0.0410*</td></tr><tr><td>Stage IV</td><td>3.411</td><td>1.048 – 12.083</td><td>0.03*</td></tr><... |
69fa37cf648fb92c4eaf0931b5f1b44fc3cd94bd765efc977f1a6282024d4502.png | complex | <table><tr><td>Whole group, <i>n</i> = 92</td><td></td><td></td><td></td><td></td></tr><tr><td>Age (median) 59.5 years</td><td></td><td></td><td></td><td></td></tr><tr><td>Gender:</td><td>Male</td><td>32 (35 %)</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>60 (65 %)</td><td></td><td></td></tr><tr><td>Treat... | <table><tr><td>Whole group, n = 92</td><td></td><td></td><td></td><td></td></tr><tr><td>Age (median) 59.5 years</td><td></td><td></td><td></td><td></td></tr><tr><td>Gender:</td><td>Male</td><td>32 (35 %)</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>60 (65 %)</td><td></td><td></td></tr><tr><td>Treatment in... | <table><tr><td>Whole group, n = 92</td><td></td><td></td><td></td><td></td></tr><tr><td>Age (median) 59.5 years</td><td></td><td></td><td></td><td></td></tr><tr><td>Gender:</td><td>Male</td><td>32 (35 %)</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>60 (65 %)</td><td></td><td></td></tr><tr><td>Treatment in... |
f3befa0868f3a729dda32df32705da2f3164358b8bfdbe617a13acb207ba4013.png | simple | <table><tr><td></td><td>Cell line</td><td>EC50 of MTX</td></tr><tr><td>MCF-7</td><td>human breast adenocarcinoma</td><td>2.58 × 10<sup>−8</sup>M</td></tr><tr><td>MDA-MB 231</td><td>human breast adenocarcinoma</td><td>5.06 × 10<sup>−7</sup>M</td></tr><tr><td>T-24</td><td>human bladder carcinoma</td... | <table><tr><td></td><td>Cell line</td><td>EC50 of MTX</td></tr><tr><td>MCF-7</td><td>human breast adenocarcinoma</td><td>2.58 × 10−8M</td></tr><tr><td>MDA-MB 231</td><td>human breast adenocarcinoma</td><td>5.06 × 10−7M</td></tr></table> | <table><tr><td></td><td>Cell line</td><td>EC50 of MTX</td></tr><tr><td>T-24</td><td>human bladder carcinoma</td><td>8.07 × 10−8M</td></tr><tr><td>PANC-1</td><td>human pancreatic carcinoma</td><td>2.34 × 10−8M</td></tr><tr><td>HT29</td><td>human colon adenocarcinoma</td><td>6.09 × 10−8M</td></tr><tr><td>A375</td><td>hum... |
4d2ca6421488a92ec8b78c4845618a3401f2f106503b40c539f1c1f16f45a119.png | complex | <table><tr><td>Estimators</td><td colspan="3">WF population</td><td colspan="3">BF population</td></tr><tr><td>BREAST CANCER</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td></tr><tr><td>Observed rates</td><td>0.973</td><td>0.974</td><td>0.975</td><td... | <table><tr><td>Estimators</td><td colspan="3">WF population</td><td colspan="3">BF population</td></tr><tr><td>BREAST CANCER</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td></tr><tr><td>Observed rates</td><td>0.973</td><td>0.974</td><td>0.975</td><td... | <table><tr><td>Estimators</td><td colspan="3">WF population</td><td colspan="3">BF population</td></tr><tr><td>Local Empirical Bayes</td><td>0.964</td><td>0.952</td><td>0.971</td><td>0.899</td><td>0.782</td><td>0.921</td></tr><tr><td>Poisson kriging (true γR(h))</td><td>0.971</td><td>0.972</td><td>0.947</td><td>0.716</... |
6f941f48002860cf9a72f0121cc8fce78c2e41bdbe443e81f6a6f7e229ef503b.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">MCC 24</td><td colspan="3">CCC 46</td><td colspan="3">ACC 21</td><td colspan="3">MCC 46</td><td colspan="3">CCC 37</td><td colspan="3">MCC 35</td></tr><tr><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</... | <table><tr><td rowspan="2"></td><td colspan="3">MCC 24</td><td colspan="3">CCC 46</td><td colspan="3">ACC 21</td><td colspan="3">MCC 46</td><td>CCC 37</td></tr><tr><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td></tr><tr><td>O/IR + FLL</t... | <table><tr><td colspan="2">CCC 37</td><td colspan="3">MCC 35</td></tr><tr><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td></tr><tr><td>37</td><td>4</td><td>25</td><td>42</td><td>15</td></tr><tr><td>32</td><td>4</td><td>30</td><td>39</td><td>13</td></tr></table> |
f10d7237b1de8a1ffb966fa36e95460a79ee4d84de915481d5bf8777b32f0a3f.png | simple | <table><tr><td>Strain name</td><td>Genotype</td><td>Reference</td></tr><tr><td>yMD7</td><td><i>MAT</i>a<i>ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg</i></td><td>This study</td></tr><tr><td></td><td><i>pep4::KanMX</i></td><td></td></tr><tr><td></td><td><i>MCM6::MCM6-3</i> × <i>FLAG (Nat-NT2)</i><... | <table><tr><td>Strain name</td><td>Genotype</td><td>Reference</td></tr><tr><td>yMD7</td><td>MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg</td><td>This study</td></tr><tr><td></td><td>pep4::KanMX</td><td></td></tr><tr><td></td><td>MCM6::MCM6-3 × FLAG (Nat-NT2)</td><td></td></tr><tr><td>yMD8</td><td>M... | <table><tr><td>yMD17</td><td>MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2) RAD9/rad9Δ::KanMX</td><td>This study</td></tr></table> |
97a29f38d180e4c3caa14553eed0f6a7cf471d5091ec275176aec44bddd00b1c.png | simple | <table><tr><td>CMP Solutions</td><td><i>c</i><sub>KDP</sub>/mM</td><td>MRR/(nm/min)</td><td>RMS/nm</td></tr><tr><td>1</td><td>0</td><td>605</td><td>3.1</td></tr><tr><td>2</td><td>10</td><td>476</td><td>2.3</td></tr><tr><td>3</td><td>20</td><td>334</td><td>1.7</td></tr><tr><td>4</td><td>30</td><td>251</td><td>1.5</td></... | <table><tr><td>CMP Solutions</td><td>cKDP/mM</td><td>MRR/(nm/min)</td><td>RMS/nm</td></tr><tr><td>1</td><td>0</td><td>605</td><td>3.1</td></tr><tr><td>2</td><td>10</td><td>476</td><td>2.3</td></tr><tr><td>3</td><td>20</td><td>334</td><td>1.7</td></tr><tr><td>4</td><td>30</td><td>251</td><td>1.5</td></tr></table> | <table><tr><td>CMP Solutions</td><td>cKDP/mM</td><td>MRR/(nm/min)</td><td>RMS/nm</td></tr><tr><td>5</td><td>40</td><td>187</td><td>1.8</td></tr><tr><td>6</td><td>50</td><td>156</td><td>2.3</td></tr><tr><td>7</td><td>80</td><td>142</td><td>2.7</td></tr><tr><td>8</td><td>100</td><td>138</td><td>2.8</td></tr></table> |
2875359f1940e6cd7d25209ea0c0513067289853c902d0d2486d8aac997f75d9.png | complex | <table><tr><td></td><td>Derivation <i>n</i> = 1420</td><td>Validation <i>n</i> = 3949</td><td><i>p</i>-value</td></tr><tr><td>Age<sup>a</sup></td><td>73.4 (10.0)</td><td>72.7 (10.7)</td><td>0.07</td></tr><tr><td>Sex (% male)</td><td>1275 (89.8)</td><td>3375 (85.5)</td><td>< 0.0001</td></tr><tr><td>FEV1%</td><td>45.2... | <table><tr><td></td><td>Derivation n = 1420</td><td>Validation n = 3949</td><td>p-value</td></tr><tr><td>Agea</td><td>73.4 (10.0)</td><td>72.7 (10.7)</td><td>0.07</td></tr><tr><td>Sex (% male)</td><td>1275 (89.8)</td><td>3375 (85.5)</td><td>< 0.0001</td></tr><tr><td>FEV1%</td><td>45.2 (16.2)</td><td>45.3 (16.6)</td><td... | <table><tr><td>morbidity Indexa</td><td>70 (1.8)</td><td>9 (1.7)</td><td>001</td></tr><tr><td>1–2</td><td>795 (56.0)</td><td>2865 (72.5)</td><td></td></tr><tr><td>≥ 3</td><td>625 (44.0)</td><td>1084 (27.4)</td><td></td></tr><tr><td>Ischaemic heart disease</td><td>205 (15.7)</td><td>505 (12.8)</td><td>0.008</td></tr><tr... |
5433609c86d5b46fbdb1f80ed68792d056b34e4c77dd85dadb011a2765c43a20.png | simple | <table><tr><td></td><td>Men (<i>n</i> = 29)</td><td>Women (<i>n</i> = 31)</td></tr><tr><td>Age (years)</td><td>40 (21–64, sd = 11.48)</td><td>37 (23–57, sd = 9.77)</td></tr><tr><td>Body mass (kg)</td><td>80.1 (53.9–130.6, sd = 13.25)</td><td>61.7 (47.8–89.2, sd = 12.91)</td></tr><tr><td>Height (... | <table><tr><td></td><td>Men (n = 29)</td><td>Women (n = 31)</td></tr></table> | <table><tr><td>Age (years)</td><td>40 (21–64, sd = 11.48)</td><td>37 (23–57, sd = 9.77)</td></tr><tr><td>Body mass (kg)</td><td>80.1 (53.9–130.6, sd = 13.25)</td><td>61.7 (47.8–89.2, sd = 12.91)</td></tr><tr><td>Height (cm)</td><td>179.0 (159.1–190.0, sd = 7.81)</td><td>165.9 (154.4–184.2, sd = 7.90)</td></tr><tr><td>B... |
ded94dc35f8cdccfb09310797537210b6dd7be41dbf7f630f9a231be88918708.png | simple | <table><tr><td></td><td>KEGG ID</td><td>KEGG term</td><td>Hypergeometric<i>P</i>-value</td><td>Corrected<i>P</i>-value (BF)</td></tr><tr><td></td><td>hsa05200</td><td>Pathways in cancer</td><td>6.16E−08</td><td>1.23E−05</td></tr><tr><td></td><td>hsa04110</td><td>Cell cycle</td><td>7.96E−08</td><td>1.5... | <table><tr><td></td><td>KEGG ID</td><td>KEGG term</td><td>HypergeometricP-value</td><td>CorrectedP-value (BF)</td></tr><tr><td></td><td>hsa05200</td><td>Pathways in cancer</td><td>6.16E−08</td><td>1.23E−05</td></tr><tr><td></td><td>hsa04110</td><td>Cell cycle</td><td>7.96E−08</td><td>1.58E−05</td></tr><tr><td></td><td>... | <table><tr><td></td><td>KEGG ID</td><td>KEGG term</td><td>HypergeometricP-value</td><td>CorrectedP-value (BF)</td></tr><tr><td>Down</td><td>hsa04520</td><td>Adherens junction</td><td>2.55E−07</td><td>5.08E−05</td></tr><tr><td></td><td>hsa04310</td><td>Wnt signaling pathway</td><td>1.16E−06</td><td>2.31E−04</td></tr><tr... |
7f8729a02d768d2ab42447e2ecb43e47610c7a70357b888b5df69462c6b2ed25.png | complex | <table><tr><td rowspan="2">plasma DBP (<i>μ</i>g/mL)</td><td colspan="2">GAgP group (<i>n</i> = 59)</td><td colspan="2">Control group (<i>n</i> = 58)</td></tr><tr><td><i>r </i></td><td><i>P</i> value</td><td><i>r </i></td><td><i>P</i> value</td></tr><tr><td>Mean BI</td><td>0.1588</td><td>0.251</td><td>0.048</td><t... | <table><tr><td rowspan="2">plasma DBP (μg/mL)</td><td colspan="2">GAgP group (n = 59)</td><td colspan="2">Control group (n = 58)</td></tr><tr><td>r</td><td>P value</td><td>r</td><td>P value</td></tr><tr><td>Mean BI</td><td>0.1588</td><td>0.251</td><td>0.048</td><td>0.768</td></tr><tr><td>Mean PD</td><td>−0.1347</td><td... | <table><tr><td rowspan="2">plasma DBP (μg/mL)</td><td colspan="2">GAgP group (n = 59)</td><td colspan="2">Control group (n = 58)</td></tr><tr><td>r</td><td>P value</td><td>r</td><td>P value</td></tr><tr><td>Mean AL</td><td>−0.164</td><td>0.230</td><td>None</td><td>—</td></tr><tr><td>Severe sites %</td><td>−0.167</td><t... |
4c41e43aa2b324f367de1b1aa57ae79b8c5a4ce14e33c28a753120a1ecf3a69f.png | simple | <table><tr><td>NCC material</td><td>After 48 h</td><td>After 336 h</td><td>After 336 h + freezing and thawing</td></tr><tr><td>Untreated</td><td>−</td><td>−</td><td>+</td></tr><tr><td>10 kGy</td><td>+</td><td>+</td><td>+</td></tr><tr><td>20 kGy</td><td>+/− <sup>1</sup></td><td>+</td><td>+</td></tr><tr... | <table><tr><td>NCC material</td><td>After 48 h</td><td>After 336 h</td><td>After 336 h + freezing and thawing</td></tr></table> | <table><tr><td>Untreated</td><td>−</td><td>−</td><td>+</td></tr><tr><td>10 kGy</td><td>+</td><td>+</td><td>+</td></tr><tr><td>20 kGy</td><td>+/− 1</td><td>+</td><td>+</td></tr><tr><td>30 kGy</td><td>−</td><td>+/− 1</td><td>+</td></tr><tr><td>40 kGy</td><td>−</td><td>+/− 1</td><td>+</td></tr><tr><td>50 kGy</td><td>−</td... |
a933e072a8010018458aca96e0c3472b93547f41f44f0f6e0e2dbe42987df62b.png | simple | <table><tr><td>Group</td><td>Mean calluses width, mm ± SD</td><td>Mean calluses length, mm ± SD</td><td>Regeneration zones ± SD</td><td>Embryogenesis appearance, %</td></tr><tr><td>Control</td><td>4.18 ± 1.36</td><td>6.22 ± 0.67</td><td>1.24 ± 0.48</td><td>20</td></tr><tr><td>AgNPs</td><td... | <table><tr><td>Group</td></tr><tr><td>Control</td></tr><tr><td>AgNPs</td></tr><tr><td>AuNPs</td></tr></table> | <table><tr><td>Mean calluses width, mm ± SD</td><td>Mean calluses length, mm ± SD</td><td>Regeneration zones ± SD</td><td>Embryogenesis appearance, %</td></tr><tr><td>4.18 ± 1.36</td><td>6.22 ± 0.67</td><td>1.24 ± 0.48</td><td>20</td></tr><tr><td>5.37 ± 3.47</td><td>7.00 ± 2.54</td><td>2.01 ± 0.98</td><td>34</td></tr><... |
4f9db0b7f2d4761467f767ff81ff0ad317c3c7dc06a12cf53eaf5a13c773d1be.png | simple | <table><tr><td>Surgery</td><td>Ratio between post-discharge SSIs and in-hospital SSIs</td></tr><tr><td>Vascular surgery</td><td>0</td></tr><tr><td>Breast surgery</td><td>3,4</td></tr><tr><td>Cesarean section</td><td>2,5</td></tr><tr><td>Cholecistectomy</td><td>1,2</td></tr><tr><td>Gastric surgery</td><td>0,4</td></tr><... | <table><tr><td>Surgery</td><td>Ratio between post-discharge SSIs and in-hospital SSIs</td></tr><tr><td>Vascular surgery</td><td>0</td></tr><tr><td>Breast surgery</td><td>3,4</td></tr><tr><td>Cesarean section</td><td>2,5</td></tr><tr><td>Cholecistectomy</td><td>1,2</td></tr><tr><td>Gastric surgery</td><td>0,4</td></tr><... | <table><tr><td>Appendectomy</td><td>0,2</td></tr><tr><td>Colon surgery</td><td>0,1</td></tr><tr><td>Hernia repair</td><td>1,4</td></tr><tr><td>Abdominal hysterectomy</td><td>0,6</td></tr><tr><td>Vaginal hysterectomy</td><td>1</td></tr></table> |
fc0f1932aaa4617e32418f5652e9399f5f421cb1fe0c1123d415330a5034b842.png | complex | <table><tr><td>Outcome Measures</td><td>Importance</td><td>Validity</td><td>Scientific soundness</td><td>Usability</td><td>Feasibility</td><td>Ranking</td></tr><tr><td>CGI-SCH</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>HIGH</td><td rowspan="8">1</td></tr><tr><td>Degree of involvement in vocational rehabi... | <table><tr><td>Outcome Measures</td><td>Importance</td><td>Validity</td><td>Scientific soundness</td><td>Usability</td><td>Feasibility</td><td>Ranking</td></tr></table> | <table><tr><td>CGI-SCH</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>HIGH</td><td rowspan="8">1</td></tr><tr><td>Degree of involvement in vocational rehabilitation</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>HIGH</td></tr><tr><td>Brief Psychiatric Rating Scale</td><td>MED</td><td>HIGH</td><td>... |
3ae47eecde0121925586e7f2a179799bcb56f86d8d19c01ba93731b46835b496.png | simple | <table><tr><td>Ingenuity Canonical Pathway<sup>a</sup></td><td>C2<sup>b</sup></td><td>C3</td><td>C4</td></tr><tr><td>Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F</td><td>3.47E-08</td><td></td><td></td></tr><tr><td>Communication between Innate and Adaptive Immune Cel... | <table><tr><td>Ingenuity Canonical Pathwaya</td><td>C2b</td><td>C3</td><td>C4</td></tr><tr><td>Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F</td><td>3.47E-08</td><td></td><td></td></tr><tr><td>Communication between Innate and Adaptive Immune Cells</td><td>6.17E-08</t... | <table><tr><td>Ingenuity Canonical Pathwaya</td><td>C2b</td><td>C3</td><td>C4</td></tr><tr><td>Macrophages</td><td>905</td><td></td><td></td></tr><tr><td>G-Protein Coupled Receptor Signaling</td><td></td><td>0.006166</td><td></td></tr><tr><td>Role of PI3K/AKT Signaling in the Pathogenesis of Influenza</td><td></td><td>... |
8e44a476eef7f00401a957e278480426f348ff78a3ee41c9d64153c3cfb2df88.png | simple | <table><tr><td>Characteristic</td><td>Burkina Faso*</td><td>Senegal*</td><td>Niger*</td><td>Ghana*</td></tr><tr><td>Surveillance design</td><td>Prospective</td><td>Retrospective</td><td>Retrospective</td><td>Prospective</td></tr><tr><td>Geographic extent</td><td>Three districts</td><td>Dakar</td><td>Niamey</td><td>Nort... | <table><tr><td>Characteristic</td></tr><tr><td>Surveillance design</td></tr><tr><td>Geographic extent</td></tr><tr><td>Surveillance population</td></tr><tr><td>Rural/Urban</td></tr><tr><td>Study years</td></tr><tr><td>Microbiological methods</td></tr><tr><td>Number of confirmed pneumococcal meningitis cases</td></tr><t... | <table><tr><td>Burkina Faso*</td><td>Senegal*</td><td>Niger*</td><td>Ghana*</td></tr><tr><td>Prospective</td><td>Retrospective</td><td>Retrospective</td><td>Prospective</td></tr><tr><td>Three districts</td><td>Dakar</td><td>Niamey</td><td>Northern area</td></tr><tr><td>880,000</td><td>950,000</td><td>550,000</td><td>14... |
b1c98e163e84880e0adfbfb440c1f5edfe682615714d00fff57ec17dbf3dd55c.png | simple | <table><tr><td>Algal species</td><td>Protein</td><td>Carbohydrates</td><td>Lipids</td></tr><tr><td><i>Anabaena cylindrica</i>[96]</td><td>43–56</td><td>25–30</td><td>4–7</td></tr><tr><td><i>Aphanizomenon flos-aquae</i>[96]</td><td>62</td><td>23</td><td>3</td></tr><tr><td><i>Chlamydomonas reinhardtii</... | <table><tr><td>Algal species</td></tr><tr><td>Anabaena cylindrica[96]</td></tr><tr><td>Aphanizomenon flos-aquae[96]</td></tr><tr><td>Chlamydomonas reinhardtii[96]</td></tr><tr><td>Chlorella minutissima[21]</td></tr><tr><td>Auxenochlorella protothecoides[97]</td></tr><tr><td>Auxenochlorella protothecoides[21]</td></tr><... | <table><tr><td>Protein</td><td>Carbohydrates</td><td>Lipids</td></tr><tr><td>43–56</td><td>25–30</td><td>4–7</td></tr><tr><td>62</td><td>23</td><td>3</td></tr><tr><td>48</td><td>17</td><td>21</td></tr><tr><td>9–24</td><td>14–42</td><td>31–57</td></tr><tr><td>11–26</td><td>17–24</td><td>25–54</td></tr><tr><td>36–38</td>... |
88446de0973a26c0ad92a04ecf1af666688e72a8ce72488a764dd2f9927ebfc0.png | complex | <table><tr><td rowspan="3">Factors</td><td colspan="3">Post-progression survival</td></tr><tr><td>Hazard ratio</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age (years) at the beginning of first-line treatment</td><td>0.98</td><td>0.94–1.02</td><td>0.47</td></tr><tr><td>Chemoradiotherapy (sequential/conc... | <table><tr><td rowspan="2">Factors</td><td colspan="3">Post-progression survival</td></tr><tr><td>Hazard ratio</td><td>95% CI</td><td>p-value</td></tr></table> | <table><tr><td>Factors</td><td colspan="3"></td></tr><tr><td>Age (years) at the beginning of first-line treatment</td><td>0.98</td><td>0.94–1.02</td><td>0.47</td></tr><tr><td>Chemoradiotherapy (sequential/concurrent)</td><td>2.25</td><td>0.66–7.04</td><td>0.18</td></tr><tr><td>Best response at second-line treatment (No... |
7465409247879ef130e80f9b8fb2cb5d68e2f4bd03c9c26fc3511b6111fb00c2.png | simple | <table><tr><td>Route</td><td><i>N</i></td><td>(%)</td></tr><tr><td>Internet</td><td>2511</td><td>(42.0)</td></tr><tr><td>TV or Movie</td><td>3185</td><td>(53.2)</td></tr><tr><td>Retail Store</td><td>2138</td><td>(35.7)</td></tr><tr><td>Billboard</td><td>810</td><td>(13.6)</td></tr><tr><td>Vehicle</td><td>483</td><td>(8... | <table><tr><td>Route</td></tr><tr><td>Internet</td></tr><tr><td>TV or Movie</td></tr><tr><td>Retail Store</td></tr><tr><td>Billboard</td></tr><tr><td>Vehicle</td></tr><tr><td>Event</td></tr><tr><td>Magazine or newspaper</td></tr></table> | <table><tr><td>N</td><td>(%)</td></tr><tr><td>2511</td><td>(42.0)</td></tr><tr><td>3185</td><td>(53.2)</td></tr><tr><td>2138</td><td>(35.7)</td></tr><tr><td>810</td><td>(13.6)</td></tr><tr><td>483</td><td>(8.1)</td></tr><tr><td>686</td><td>(11.5)</td></tr><tr><td>2062</td><td>(34.9)</td></tr></table> |
2b8b816ebc6cc7b0e62585f3c2874ca5afa578fd984e30270fa966feaa99cb72.png | simple | <table><tr><td>SLE patients</td><td>No lupus nephritis(α)</td><td>Lupus nephritis(β)</td><td>p-value</td></tr><tr><td>Gender (female: male)</td><td>53:3</td><td>17:5</td><td>0.03*</td></tr><tr><td></td><td>mean± standard deviation (<i>n</i> = 56)</td><td>mean± standard deviation (<i>n</i> = 22)</td>... | <table><tr><td>SLE patients</td></tr><tr><td>Gender (female: male)</td></tr><tr><td></td></tr><tr><td>Age (year)</td></tr><tr><td>Leukocytes (×1000/ml)</td></tr><tr><td>Hemoglobulin (mg/dL)</td></tr><tr><td>Neutrophil (%)</td></tr><tr><td>Lymphocyte (%)</td></tr><tr><td>Platelets (1000/μL)</td></tr><tr><td>Alanine amin... | <table><tr><td>No lupus nephritis(α)</td><td>Lupus nephritis(β)</td><td>p-value</td></tr><tr><td>53:3</td><td>17:5</td><td>0.03*</td></tr><tr><td>mean± standard deviation (n = 56)</td><td>mean± standard deviation (n = 22)</td><td></td></tr><tr><td>28.72±14.87</td><td>28.3±14.79</td><td>0.91</td></tr><tr><td>5.73±2.92</... |
08347f0e7444b132300154ee1bcca2f2d62892fc8b02f09563394dfd1aee85d3.png | simple | <table><tr><td>Species</td><td>Exon A</td><td>Exon B</td><td>Exon C</td><td>Exon D</td><td>Exon E</td><td>Exon F</td><td>Identity</td></tr><tr><td>Horse</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>130</td><td>100.0</td></tr><tr><td>Cat</td><td>1477</td><td>86</td><td>206</td><td>133</td><td>134<... | <table><tr><td>Species</td><td>Exon A</td><td>Exon B</td><td>Exon C</td><td>Exon D</td><td>Exon E</td><td>Exon F</td><td>Identity</td></tr><tr><td>Horse</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>130</td><td>100.0</td></tr><tr><td>Cat</td><td>1477</td><td>86</td><td>206</td><td>133</td><td>134<... | <table><tr><td>Species</td><td>Exon A</td><td>Exon B</td><td>Exon C</td><td>Exon D</td><td>Exon E</td><td>Exon F</td><td>Identity</td></tr><tr><td>an</td><td>80</td><td>86</td><td>206</td><td>3</td><td>4</td><td>187</td><td></td></tr><tr><td>Rhesus</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187... |
2edb4d60d6e22abaf32211a0fd109e4d6d3c7c91db1de2365021af7c6aa3cdc7.png | simple | <table><tr><td></td><td>Autism Spectrum Disorder <i>M</i> (<i>SD</i>)</td><td>Down Syndrome <i>M</i> (<i>SD</i>)</td><td>Typical development <i>M</i> (<i>SD</i>)</td></tr><tr><td>Exploratory play</td><td>0.29 (1.49)</td><td>-0.11 (0.66)</td><td>0.17 (0.83)</td></tr><tr><td>(1) Unitary functional activity</td><td>1.67 (... | <table><tr><td></td><td>Autism Spectrum Disorder M (SD)</td><td>Down Syndrome M (SD)</td><td>Typical development M (SD)</td></tr><tr><td>Exploratory play</td><td>0.29 (1.49)</td><td>-0.11 (0.66)</td><td>0.17 (0.83)</td></tr><tr><td>(1) Unitary functional activity</td><td>1.67 (2.09)</td><td>0.49 (0.78)</td><td>0.73 (0.... | <table><tr><td>(8) Substitution pretense</td><td>-0.55 (0.00)</td><td>-0.52 (0.11)</td><td>-0.54 (0.09)</td></tr></table> |
e940e440732d5a3ad2183fcb1a373041c029b5fc2b9d2940357799ebcb081e85.png | complex | <table><tr><td colspan="2">Cohort 3</td><td>Patients with ∆ reticulin and/or collagen<sup>a</sup> (<i>N</i> = 7)</td><td>Patients with no ∆ collagen or reticulin (<i>N</i> = 51)</td></tr><tr><td colspan="2">Age, median (Q1, Q3), years</td><td>47 (30, 60)</td><td>44 (33, 61)</td></tr><tr><td colspan="2">ITP ... | <table><tr><td colspan="2">Cohort 3</td><td>Patients with ∆ reticulin and/or collagena (N = 7)</td><td>Patients with no ∆ collagen or reticulin (N = 51)</td></tr><tr><td colspan="2">Age, median (Q1, Q3), years</td><td>47 (30, 60)</td><td>44 (33, 61)</td></tr><tr><td colspan="2">ITP duration, median (Q1, Q3), years</td>... | <table><tr><td rowspan="2">Platelet responseb, median (Q1, Q3)</td><td>Time to first platelet response, weeks</td><td>15 (7, 21)c</td><td>3 (2, 8)d</td></tr><tr><td>Weeks with platelet response, %</td><td>5 (0, 28)</td><td>38 (28, 76)</td></tr><tr><td rowspan="3">Exposuree, median (Q1, Q3)</td><td>Average weekly dose, ... |
14f81461f0f9993500fad766ae21b5c94ced6e64f205832dd2cc25f8fdf8f5bd.png | simple | <table><tr><td>Pollen recipient (♀)</td><td>Pollen donor (♂)</td><td>Number of flowers</td><td>Number of fruits</td><td>Fruit set (%)</td><td>Mean number of seeds per fruit</td><td>Seed viability (%)</td><td>Mean number of viable seeds per fruit<sup>a</sup></td></tr><tr><td><i>B. crispa</i></td><td><i>B. cr... | <table><tr><td>Pollen recipient (♀)</td><td>Pollen donor (♂)</td><td>Number of flowers</td><td>Number of fruits</td><td>Fruit set (%)</td><td>Mean number of seeds per fruit</td><td>Seed viability (%)</td><td>Mean number of viable seeds per fruita</td></tr><tr><td>B. crispa</td><td>B. crispa</td><td>20</td><td>11</td><t... | <table><tr><td></td><td>Putative hybrid</td><td>37</td><td>18</td><td>48</td><td>1.94</td><td>57</td><td>1.11</td></tr><tr><td>Putative hybrid</td><td>B. crispa</td><td>31</td><td>19</td><td>61</td><td>2.79</td><td>0</td><td>0.00</td></tr><tr><td></td><td>B. officinalis</td><td>38</td><td>32</td><td>84</td><td>4.63</td... |
19600379292ab6ee8ec50e297db7c6bc6a50364eb4f3705cb2e3318165f40f83.png | simple | <table><tr><td></td><td>control</td><td>LBBB</td></tr><tr><td>n</td><td>100</td><td>33</td></tr><tr><td>males, n (%)</td><td>64 (64.0%)</td><td>23 (69.7%)</td></tr><tr><td>age, years</td><td>52.5 ± 16.9</td><td>69.7 ± 9.1</td></tr><tr><td>QRS, ms</td><td>82.4 ± 4.2</td><td>149.7 ± 15.5</td></tr><tr>... | <table><tr><td></td><td>control</td><td>LBBB</td></tr><tr><td>n</td><td>100</td><td>33</td></tr><tr><td>males, n (%)</td><td>64 (64.0%)</td><td>23 (69.7%)</td></tr><tr><td>age, years</td><td>52.5 ± 16.9</td><td>69.7 ± 9.1</td></tr><tr><td>QRS, ms</td><td>82.4 ± 4.2</td><td>149.7 ± 15.5</td></tr><tr><td>LVEF, %</td><td>... | <table><tr><td></td><td>control</td><td>LBBB</td></tr><tr><td>valvular, n (%)</td><td>-</td><td>1 (3.0%)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.